Search

Your search keyword '"Ormeci N"' showing total 110 results
Start Over Author "Ormeci N"
110 results on '"Ormeci N"'

1. Liver involvement in patients with brucellosis: results of the Marmara study

Author

Ozturk-Engin, D., Erdem, H., Gencer, S., Kaya, S., Baran, A. I., Batirel, A., Tekin, R., Celen, M. K., Denk, A., Guler, S., Ulug, M., Turan, H., Pekok, A. U., Mermut, G., Kaya, S., Tasbakan, M., Tulek, N., Cag, Y., Inan, A., Yalci, A., Ataman-Hatipoglu, C., Gonen, I., Dogan-Celik, A., Bozkurt, F., Gulsun, S., Sunnetcioglu, M., Guven, T., Duygu, F., Parlak, E., Sozen, H., Tosun, S., Demirdal, T., Guclu, E., Karabay, O., Uzun, N., Gunal, O., Diktas, H., Haykir-Solay, A., Erbay, A., Kader, C., Aydin, O., Erdem, A., Elaldi, N., Kadanali, A., Yulugkural, Z., Gorenek, L., Altındis, M., Bolukcu, S., Agalar, C., and Ormeci, N.

Published
2014
Full Text
View/download PDF

2. The case for simplifying and using absolute targets for viral hepatitis elimination goals

Author

Razavi, H. Blach, S. Razavi-Shearer, D. Abaalkhail, F. Abbas, Z. Abdallah, A. Abrao Ferreira, P. Abu Raddad, L.J. Adda, D. Agarwal, K. Aghemo, A. Ahmed, A. Al-Busafi, S.A. Al-hamoudi, W. Al-Kaabi, S. Al-Romaihi, H. Aljarallah, B. AlNaamani, K. Alqahtani, S. Alswat, K. Altraif, I. Asselah, T. Bacon, B. Bessone, F. Bizri, A.R. Block, T. Bonino, F. Brandão-Mello, C.E. Brown, K. Bruggmann, P. Brunetto, M.R. Buti, M. Cabezas, J. Calleja, J.L. Castro Batänjer, E. Chan, H.L.-Y. Chang, H. Chen, C.-J. Christensen, P.B. Chuang, W.-L. Cisneros, L. Cohen, C. Colombo, M. Conway, B. Cooper, C. Craxi, A. Crespo, J. Croes, E. Cryer, D. Cupertino de Barros, F.P. Derbala, M. Dillon, J. Doss, W. Dou, X. Doyle, J. Duberg, A.-S. Dugan, E. Dunn, R. Dusheiko, G. El Khayat, H. El-Sayed, M.H. Eshraghian, A. Esmat, G. Esteban Mur, R. Ezzat, S. Falconer, K. Fassio, E. Ferrinho, P. Flamm, S. Flisiak, R. Foster, G. Fung, J. García-Samaniego, J. Gish, R.G. Gonçales, F. Halota, W. Hamoudi, W. Hassany, M. Hatzakis, A. Hay, S. Himatt, S. Hoepelman, I.M. Hsu, Y.-C. Hui, Y.T. Hunyady, B. Jacobson, I. Janjua, N. Janssen, H. Jarcuska, P. Kabagambe, K. Kanto, T. Kao, J.-H. Kaymakoglu, S. Kershenobich, D. Khamis, F. Kim, D.J. Kim, D.Y. Kondili, L.A. Kottilil, S. Kramvis, A. Kugelmas, M. Kurosaki, M. Lacombe, K. Lagging, M. Lao, W.-C. Lavanchy, D. Lazarus, J.V. Lee, A. Lee, S.S. Levy, M. Liakina, V. Lim, Y.-S. Liu, S. Maddrey, W. Malekzadeh, R. Marinho, R.T. Mathur, P. Maticic, M. Mendes Correa, M.C. Mera, J. Merat, S. Mogawer, S. Mohamed, R. Muellhaupt, B. Muljono, D. Mostafa, I. Nahum, M.S. Nawaz, A. Negro, F. Ninburg, M. Ning, Q. Ntiri- Reid, B. Nymadawa, P. Oevrehus, A. Ormeci, N. Orrego, M. Osman, A. Oyunsuren, T. Pan, C. Papaevangelou, V. Papatheodoridis, G. Popping, S. Prasad, P. Prithiviputh, R. Qureshi, H. Ramji, A. Razavi-Shearer, K. Reddy, R. Remak, W. Richter, C. Ridruejo, E. Robaeys, G. Roberts, S. Roberts, L. Roudot-Thoraval, F. Saab, S. Said, S. Salamat, A. Sanai, F. Sanchez-Avila, J.F. Schiff, E. Schinazi, R. Sebastiani, G. Seguin-Devaux, C. Shanmugam, R.P. Sharara, A. Shilton, S. Shouval, D. Sievert, W. Simonova, M. Sohrabpour, A.A. Sonderup, M. Soza, A. Wendy Spearman, C. Steinfurth, N. Sulkowski, M. Tan, S.-S. Tanaka, J. Tashi, D. Thein, H.-H. Thompson, P. Tolmane, I. Toy, M. Valantinas, J. Van de Vijver, D. Vélez-Möller, P. Vince, A. Waked, I. Wang, S. Wedemeyer, H. Wong, V. Xie, Q. Yamada, S. Yang, H.-I. Yesmembetov, K. Yilmaz, Y. Younossi, Z. Yu, M.-L. Yuen, M.-F. Yurdaydin, C. Yusuf, A. Zekry, A. Zeuzem, S. Polaris Observatory Collaborators

Subjects
digestive system diseases
Abstract

The 69th World Health Assembly endorsed the Global Health Sector Strategy for Viral Hepatitis, embracing a goal to eliminate hepatitis infection as a public health threat by 2030. This was followed by the World Health Organization's (WHO) global targets for the care and management of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These announcements and targets were important in raising awareness and calling for action; however, tracking countries’ progress towards these elimination goals has provided insights to the limitations of these targets. The existing targets compare a country's progress relative to its 2015 values, penalizing countries who started their programmes prior to 2015, countries with a young population, or countries with a low prevalence. We recommend that (1) WHO simplify the hepatitis elimination targets, (2) change to absolute targets and (3) allow countries to achieve these disease targets with their own service coverage initiatives that will have the maximum impact. The recommended targets are as follows: reduce HCV new chronic cases to ≤5 per 100 000, reduce HBV prevalence among 1-year-olds to ≤0.1%, reduce HBV and HCV mortality to ≤5 per 100 000, and demonstrate HBV and HCV year-to-year decrease in new HCV- and HBV-related HCC cases. The objective of our recommendations is not to lower expectations or diminish the hepatitis elimination standards, but to provide clearer targets that recognize the past and current elimination efforts by countries, help measure progress towards true elimination, and motivate other countries to follow suit. © 2020 John Wiley & Sons Ltd

Published
2021

4. The case for simplifying and using absolute targets for viral hepatitis elimination goals

Author

Razavi, H. Blach, S. Razavi-Shearer, D. Abaalkhail, F. Abbas, Z. Abdallah, A. Abrao Ferreira, P. Abu Raddad, L.J. Adda, D. Agarwal, K. Aghemo, A. Ahmed, A. Al-Busafi, S.A. Al-hamoudi, W. Al-Kaabi, S. Al-Romaihi, H. Aljarallah, B. AlNaamani, K. Alqahtani, S. Alswat, K. Altraif, I. Asselah, T. Bacon, B. Bessone, F. Bizri, A.R. Block, T. Bonino, F. Brandão-Mello, C.E. Brown, K. Bruggmann, P. Brunetto, M.R. Buti, M. Cabezas, J. Calleja, J.L. Castro Batänjer, E. Chan, H.L.-Y. Chang, H. Chen, C.-J. Christensen, P.B. Chuang, W.-L. Cisneros, L. Cohen, C. Colombo, M. Conway, B. Cooper, C. Craxi, A. Crespo, J. Croes, E. Cryer, D. Cupertino de Barros, F.P. Derbala, M. Dillon, J. Doss, W. Dou, X. Doyle, J. Duberg, A.-S. Dugan, E. Dunn, R. Dusheiko, G. El Khayat, H. El-Sayed, M.H. Eshraghian, A. Esmat, G. Esteban Mur, R. Ezzat, S. Falconer, K. Fassio, E. Ferrinho, P. Flamm, S. Flisiak, R. Foster, G. Fung, J. García-Samaniego, J. Gish, R.G. Gonçales, F. Halota, W. Hamoudi, W. Hassany, M. Hatzakis, A. Hay, S. Himatt, S. Hoepelman, I.M. Hsu, Y.-C. Hui, Y.T. Hunyady, B. Jacobson, I. Janjua, N. Janssen, H. Jarcuska, P. Kabagambe, K. Kanto, T. Kao, J.-H. Kaymakoglu, S. Kershenobich, D. Khamis, F. Kim, D.J. Kim, D.Y. Kondili, L.A. Kottilil, S. Kramvis, A. Kugelmas, M. Kurosaki, M. Lacombe, K. Lagging, M. Lao, W.-C. Lavanchy, D. Lazarus, J.V. Lee, A. Lee, S.S. Levy, M. Liakina, V. Lim, Y.-S. Liu, S. Maddrey, W. Malekzadeh, R. Marinho, R.T. Mathur, P. Maticic, M. Mendes Correa, M.C. Mera, J. Merat, S. Mogawer, S. Mohamed, R. Muellhaupt, B. Muljono, D. Mostafa, I. Nahum, M.S. Nawaz, A. Negro, F. Ninburg, M. Ning, Q. Ntiri- Reid, B. Nymadawa, P. Oevrehus, A. Ormeci, N. Orrego, M. Osman, A. Oyunsuren, T. Pan, C. Papaevangelou, V. Papatheodoridis, G. Popping, S. Prasad, P. Prithiviputh, R. Qureshi, H. Ramji, A. Razavi-Shearer, K. Reddy, R. Remak, W. Richter, C. Ridruejo, E. Robaeys, G. Roberts, S. Roberts, L. Roudot-Thoraval, F. Saab, S. Said, S. Salamat, A. Sanai, F. Sanchez-Avila, J.F. Sch and Razavi, H. Blach, S. Razavi-Shearer, D. Abaalkhail, F. Abbas, Z. Abdallah, A. Abrao Ferreira, P. Abu Raddad, L.J. Adda, D. Agarwal, K. Aghemo, A. Ahmed, A. Al-Busafi, S.A. Al-hamoudi, W. Al-Kaabi, S. Al-Romaihi, H. Aljarallah, B. AlNaamani, K. Alqahtani, S. Alswat, K. Altraif, I. Asselah, T. Bacon, B. Bessone, F. Bizri, A.R. Block, T. Bonino, F. Brandão-Mello, C.E. Brown, K. Bruggmann, P. Brunetto, M.R. Buti, M. Cabezas, J. Calleja, J.L. Castro Batänjer, E. Chan, H.L.-Y. Chang, H. Chen, C.-J. Christensen, P.B. Chuang, W.-L. Cisneros, L. Cohen, C. Colombo, M. Conway, B. Cooper, C. Craxi, A. Crespo, J. Croes, E. Cryer, D. Cupertino de Barros, F.P. Derbala, M. Dillon, J. Doss, W. Dou, X. Doyle, J. Duberg, A.-S. Dugan, E. Dunn, R. Dusheiko, G. El Khayat, H. El-Sayed, M.H. Eshraghian, A. Esmat, G. Esteban Mur, R. Ezzat, S. Falconer, K. Fassio, E. Ferrinho, P. Flamm, S. Flisiak, R. Foster, G. Fung, J. García-Samaniego, J. Gish, R.G. Gonçales, F. Halota, W. Hamoudi, W. Hassany, M. Hatzakis, A. Hay, S. Himatt, S. Hoepelman, I.M. Hsu, Y.-C. Hui, Y.T. Hunyady, B. Jacobson, I. Janjua, N. Janssen, H. Jarcuska, P. Kabagambe, K. Kanto, T. Kao, J.-H. Kaymakoglu, S. Kershenobich, D. Khamis, F. Kim, D.J. Kim, D.Y. Kondili, L.A. Kottilil, S. Kramvis, A. Kugelmas, M. Kurosaki, M. Lacombe, K. Lagging, M. Lao, W.-C. Lavanchy, D. Lazarus, J.V. Lee, A. Lee, S.S. Levy, M. Liakina, V. Lim, Y.-S. Liu, S. Maddrey, W. Malekzadeh, R. Marinho, R.T. Mathur, P. Maticic, M. Mendes Correa, M.C. Mera, J. Merat, S. Mogawer, S. Mohamed, R. Muellhaupt, B. Muljono, D. Mostafa, I. Nahum, M.S. Nawaz, A. Negro, F. Ninburg, M. Ning, Q. Ntiri- Reid, B. Nymadawa, P. Oevrehus, A. Ormeci, N. Orrego, M. Osman, A. Oyunsuren, T. Pan, C. Papaevangelou, V. Papatheodoridis, G. Popping, S. Prasad, P. Prithiviputh, R. Qureshi, H. Ramji, A. Razavi-Shearer, K. Reddy, R. Remak, W. Richter, C. Ridruejo, E. Robaeys, G. Roberts, S. Roberts, L. Roudot-Thoraval, F. Saab, S. Said, S. Salamat, A. Sanai, F. Sanchez-Avila, J.F. Sch

Abstract

The 69th World Health Assembly endorsed the Global Health Sector Strategy for Viral Hepatitis, embracing a goal to eliminate hepatitis infection as a public health threat by 2030. This was followed by the World Health Organization's (WHO) global targets for the care and management of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These announcements and targets were important in raising awareness and calling for action; however, tracking countries’ progress towards these elimination goals has provided insights to the limitations of these targets. The existing targets compare a country's progress relative to its 2015 values, penalizing countries who started their programmes prior to 2015, countries with a young population, or countries with a low prevalence. We recommend that (1) WHO simplify the hepatitis elimination targets, (2) change to absolute targets and (3) allow countries to achieve these disease targets with their own service coverage initiatives that will have the maximum impact. The recommended targets are as follows: reduce HCV new chronic cases to ≤5 per 100 000, reduce HBV prevalence among 1-year-olds to ≤0.1%, reduce HBV and HCV mortality to ≤5 per 100 000, and demonstrate HBV and HCV year-to-year decrease in new HCV- and HBV-related HCC cases. The objective of our recommendations is not to lower expectations or diminish the hepatitis elimination standards, but to provide clearer targets that recognize the past and current elimination efforts by countries, help measure progress towards true elimination, and motivate other countries to follow suit. © 2020 John Wiley & Sons Ltd

Published
2021

5. The case for simplifying and using absolute targets for viral hepatitis elimination goals.

Author

Razavi H., Blach S., Razavi-Shearer D., Abaalkhail F., Abbas Z., Abdallah A., Abrao Ferreira P., Abu Raddad L.J., Adda D., Agarwal K., Aghemo A., Ahmed A., Al-Busafi S.A., Al-hamoudi W., Al-Kaabi S., Al-Romaihi H., Aljarallah B., AlNaamani K., Alqahtani S., Alswat K., Altraif I., Asselah T., Bacon B., Bessone F., Bizri A.R., Block T., Bonino F., Brandao-Mello C.E., Brown K., Bruggmann P., Brunetto M.R., Buti M., Cabezas J., Calleja J.L., Castro Batanjer E., Chan H.L.-Y., Chang H., Chen C.-J., Christensen P.B., Chuang W.-L., Cisneros L., Cohen C., Colombo M., Conway B., Cooper C., Craxi A., Crespo J., Croes E., Cryer D., Cupertino de Barros F.P., Derbala M., Dillon J., Doss W., Dou X., Doyle J., Duberg A.-S., Dugan E., Dunn R., Dusheiko G., El Khayat H., El-Sayed M.H., Eshraghian A., Esmat G., Esteban Mur R., Ezzat S., Falconer K., Fassio E., Ferrinho P., Flamm S., Flisiak R., Foster G., Fung J., Garcia-Samaniego J., Gish R.G., Goncales F., Halota W., Hamoudi W., Hassany M., Hatzakis A., Hay S., Himatt S., Hoepelman I.M., Hsu Y.-C., Hui Y.T., Hunyady B., Jacobson I., Janjua N., Janssen H., Jarcuska P., Kabagambe K., Kanto T., Kao J.-H., Kaymakoglu S., Kershenobich D., Khamis F., Kim D.J., Kim D.Y., Kondili L.A., Kottilil S., Kramvis A., Kugelmas M., Kurosaki M., Lacombe K., Lagging M., Lao W.-C., Lavanchy D., Lazarus J.V., Lee A., Lee S.S., Levy M., Liakina V., Lim Y.-S., Liu S., Maddrey W., Malekzadeh R., Marinho R.T., Mathur P., Maticic M., Mendes Correa M.C., Mera J., Merat S., Mogawer S., Mohamed R., Muellhaupt B., Muljono D., Mostafa I., Nahum M.S., Nawaz A., Negro F., Ninburg M., Ning Q., Ntiri- Reid B., Nymadawa P., Oevrehus A., Ormeci N., Orrego M., Osman A., Oyunsuren T., Pan C., Papaevangelou V., Papatheodoridis G., Popping S., Prasad P., Prithiviputh R., Qureshi H., Ramji A., Razavi-Shearer K., Reddy R., Remak W., Richter C., Ridruejo E., Robaeys G., Roberts S., Roberts L., Roudot-Thoraval F., Saab S., Said S., Salamat A., Sanai F., Sanchez-Avila J.F., Schiff E., Schinazi R., Sebastiani G., Seguin-Devaux C., Shanmugam R.P., Sharara A., Shilton S., Shouval D., Sievert W., Simonova M., Sohrabpour A.A., Sonderup M., Soza A., Wendy Spearman C., Steinfurth N., Sulkowski M., Tan S.-S., Tanaka J., Tashi D., Thein H.-H., Thompson P., Tolmane I., Toy M., Valantinas J., Van de Vijver D., Velez-Moller P., Vince A., Waked I., Wang S., Wedemeyer H., Wong V., Xie Q., Yamada S., Yang H.-I., Yesmembetov K., Yilmaz Y., Younossi Z., Yu M.-L., Yuen M.-F., Yurdaydin C., Yusuf A., Zekry A., Zeuzem S., Razavi H., Blach S., Razavi-Shearer D., Abaalkhail F., Abbas Z., Abdallah A., Abrao Ferreira P., Abu Raddad L.J., Adda D., Agarwal K., Aghemo A., Ahmed A., Al-Busafi S.A., Al-hamoudi W., Al-Kaabi S., Al-Romaihi H., Aljarallah B., AlNaamani K., Alqahtani S., Alswat K., Altraif I., Asselah T., Bacon B., Bessone F., Bizri A.R., Block T., Bonino F., Brandao-Mello C.E., Brown K., Bruggmann P., Brunetto M.R., Buti M., Cabezas J., Calleja J.L., Castro Batanjer E., Chan H.L.-Y., Chang H., Chen C.-J., Christensen P.B., Chuang W.-L., Cisneros L., Cohen C., Colombo M., Conway B., Cooper C., Craxi A., Crespo J., Croes E., Cryer D., Cupertino de Barros F.P., Derbala M., Dillon J., Doss W., Dou X., Doyle J., Duberg A.-S., Dugan E., Dunn R., Dusheiko G., El Khayat H., El-Sayed M.H., Eshraghian A., Esmat G., Esteban Mur R., Ezzat S., Falconer K., Fassio E., Ferrinho P., Flamm S., Flisiak R., Foster G., Fung J., Garcia-Samaniego J., Gish R.G., Goncales F., Halota W., Hamoudi W., Hassany M., Hatzakis A., Hay S., Himatt S., Hoepelman I.M., Hsu Y.-C., Hui Y.T., Hunyady B., Jacobson I., Janjua N., Janssen H., Jarcuska P., Kabagambe K., Kanto T., Kao J.-H., Kaymakoglu S., Kershenobich D., Khamis F., Kim D.J., Kim D.Y., Kondili L.A., Kottilil S., Kramvis A., Kugelmas M., Kurosaki M., Lacombe K., Lagging M., Lao W.-C., Lavanchy D., Lazarus J.V., Lee A., Lee S.S., Levy M., Liakina V., Lim Y.-S., Liu S., Maddrey W., Malekzadeh R., Marinho R.T., Mathur P., Maticic M., Mendes Correa M.C., Mera J., Merat S., Mogawer S., Mohamed R., Muellhaupt B., Muljono D., Mostafa I., Nahum M.S., Nawaz A., Negro F., Ninburg M., Ning Q., Ntiri- Reid B., Nymadawa P., Oevrehus A., Ormeci N., Orrego M., Osman A., Oyunsuren T., Pan C., Papaevangelou V., Papatheodoridis G., Popping S., Prasad P., Prithiviputh R., Qureshi H., Ramji A., Razavi-Shearer K., Reddy R., Remak W., Richter C., Ridruejo E., Robaeys G., Roberts S., Roberts L., Roudot-Thoraval F., Saab S., Said S., Salamat A., Sanai F., Sanchez-Avila J.F., Schiff E., Schinazi R., Sebastiani G., Seguin-Devaux C., Shanmugam R.P., Sharara A., Shilton S., Shouval D., Sievert W., Simonova M., Sohrabpour A.A., Sonderup M., Soza A., Wendy Spearman C., Steinfurth N., Sulkowski M., Tan S.-S., Tanaka J., Tashi D., Thein H.-H., Thompson P., Tolmane I., Toy M., Valantinas J., Van de Vijver D., Velez-Moller P., Vince A., Waked I., Wang S., Wedemeyer H., Wong V., Xie Q., Yamada S., Yang H.-I., Yesmembetov K., Yilmaz Y., Younossi Z., Yu M.-L., Yuen M.-F., Yurdaydin C., Yusuf A., Zekry A., and Zeuzem S.

Abstract

The 69th World Health Assembly endorsed the Global Health Sector Strategy for Viral Hepatitis, embracing a goal to eliminate hepatitis infection as a public health threat by 2030. This was followed by the World Health Organization's (WHO) global targets for the care and management of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These announcements and targets were important in raising awareness and calling for action; however, tracking countries' progress towards these elimination goals has provided insights to the limitations of these targets. The existing targets compare a country's progress relative to its 2015 values, penalizing countries who started their programmes prior to 2015, countries with a young population, or countries with a low prevalence. We recommend that (1) WHO simplify the hepatitis elimination targets, (2) change to absolute targets and (3) allow countries to achieve these disease targets with their own service coverage initiatives that will have the maximum impact. The recommended targets are as follows: reduce HCV new chronic cases to <=5 per 100 000, reduce HBV prevalence among 1-year-olds to <=0.1%, reduce HBV and HCV mortality to <=5 per 100 000, and demonstrate HBV and HCV year-to-year decrease in new HCV- and HBV-related HCC cases. The objective of our recommendations is not to lower expectations or diminish the hepatitis elimination standards, but to provide clearer targets that recognize the past and current elimination efforts by countries, help measure progress towards true elimination, and motivate other countries to follow suit.Copyright © 2020 John Wiley & Sons Ltd

Published
2021

10. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.

Author

Falconer K., Ormeci N., Papatheodoridis G., Pasini K., Pimenov N., Poustchi H., Quang T.D., Qureshi H., Ramji A., Razavi-Shearer K., Redae B., Reesink H.W., Rios C.Y., Rjaskova G., Robbins S., Roberts L.R., Roberts S.K., Ryder S.D., Safadi R., Sagalova O., Salupere R., Sanai F.M., Sanchez-Avila J.F., Saraswat V., Sarrazin C., Schmelzer J.D., Schreter I., Scott J., Seguin-Devaux C., Shah S.R., Sharara A.I., Sharma M., Shiha G.E., Shin T., Sperl J., Starkel P., Stedman C., Sypsa V., Tacke F., Tan S.S., Tanaka J., Tomasiewicz K., Urbanek P., van der Meer A.J., Van Vlierberghe H., Vella S., Vince A., Waheed Y., Waked I., Walsh N., Weis N., Wong V.W., Woodring J., Yaghi C., Yang H.-I., Yang C.-L., Yesmembetov K., Yosry A., Yuen M.-F., Yusuf M.A.M., Zeuzem S., Razavi H., Sievert W., Razavi-Shearer D., Gamkrelidze I., Nguyen M.H., Chen D.-S., Van Damme P., Abbas Z., Abdulla M., Abou Rached A., Adda D., Aho I., Akarca U., Al Ali F.H., Lawati F.A.L., Naamani K.A.L., Alashgar H.I., Alavian S.M., Alawadhi S., Albillos A., Al-Busafi S.A., Aleman S., Alfaleh F.Z., Aljumah A.A., Anand A.C., Anh N.T., Arends J.E., Arkkila P., Athanasakis K., Bane A., Ben-Ari Z., Berg T., Bizri A.R., Blach S., Brandao Mello C.E., Brandon S.M., Bright B., Bruggmann P., Brunetto M., Buti M., Chan H.L.Y., Chaudhry A., Chien R.-N., Choi M.S., Christensen P.B., Chuang W.-L., Chulanov V., Clausen M.R., Colombo M., Cornberg M., Cowie B., Craxi A., Croes E.A., Cuellar D.A., Cunningham C., Desalegn H., Drazilova S., Duberg A.-S., Egeonu S.S., El-Sayed M.H., Estes C., Ferraz M.L.G., Ferreira P.R., Flisiak R., Frankova S., Gaeta G.B., Garcia-Samaniego J., Genov J., Gerstoft J., Goldis A., Gountas I., Gray R., Guimaraes Pessoa M., Hajarizadeh B., Hatzakis A., Hezode C., Himatt S.M., Hoepelman A., Hrstic I., Hui Y.-T.T., Husa P., Jahis R., Janjua N.Z., Jarcuka P., Jaroszewicz J., Kaymakoglu S., Kershenobich D., Kondili L.A., Konysbekova A., Krajden M., Kristian P., Laleman W., Lao W.-C.C., Layden J., Lazarus J.V., Lee M.-H., Liakina V., Lim Y.-S.S., Loo C.-K.K., Lukic B., Malekzadeh R., Malu A.O., Mamatkulov A., Manns M., Marinho R.T., Maticic M., Mauss S., Memon M.S., Mendes Correa M.C., Mendez-Sanchez N., Merat S., Metwally A.M., Mohamed R., Mokhbat J.E., Moreno C., Mossong J., Mourad F.H., Mullhaupt B., Murphy K., Musabaev E., Nawaz A., Nde H.M., Negro F., Nersesov A., Nguyen V.T.T., Njouom R., Ntagirabiri R., Nurmatov Z., Obekpa S., Ocama P., Oguche S., Omede O., Omuemu C., Opare-Sem O., Opio C.K., Falconer K., Ormeci N., Papatheodoridis G., Pasini K., Pimenov N., Poustchi H., Quang T.D., Qureshi H., Ramji A., Razavi-Shearer K., Redae B., Reesink H.W., Rios C.Y., Rjaskova G., Robbins S., Roberts L.R., Roberts S.K., Ryder S.D., Safadi R., Sagalova O., Salupere R., Sanai F.M., Sanchez-Avila J.F., Saraswat V., Sarrazin C., Schmelzer J.D., Schreter I., Scott J., Seguin-Devaux C., Shah S.R., Sharara A.I., Sharma M., Shiha G.E., Shin T., Sperl J., Starkel P., Stedman C., Sypsa V., Tacke F., Tan S.S., Tanaka J., Tomasiewicz K., Urbanek P., van der Meer A.J., Van Vlierberghe H., Vella S., Vince A., Waheed Y., Waked I., Walsh N., Weis N., Wong V.W., Woodring J., Yaghi C., Yang H.-I., Yang C.-L., Yesmembetov K., Yosry A., Yuen M.-F., Yusuf M.A.M., Zeuzem S., Razavi H., Sievert W., Razavi-Shearer D., Gamkrelidze I., Nguyen M.H., Chen D.-S., Van Damme P., Abbas Z., Abdulla M., Abou Rached A., Adda D., Aho I., Akarca U., Al Ali F.H., Lawati F.A.L., Naamani K.A.L., Alashgar H.I., Alavian S.M., Alawadhi S., Albillos A., Al-Busafi S.A., Aleman S., Alfaleh F.Z., Aljumah A.A., Anand A.C., Anh N.T., Arends J.E., Arkkila P., Athanasakis K., Bane A., Ben-Ari Z., Berg T., Bizri A.R., Blach S., Brandao Mello C.E., Brandon S.M., Bright B., Bruggmann P., Brunetto M., Buti M., Chan H.L.Y., Chaudhry A., Chien R.-N., Choi M.S., Christensen P.B., Chuang W.-L., Chulanov V., Clausen M.R., Colombo M., Cornberg M., Cowie B., Craxi A., Croes E.A., Cuellar D.A., Cunningham C., Desalegn H., Drazilova S., Duberg A.-S., Egeonu S.S., El-Sayed M.H., Estes C., Ferraz M.L.G., Ferreira P.R., Flisiak R., Frankova S., Gaeta G.B., Garcia-Samaniego J., Genov J., Gerstoft J., Goldis A., Gountas I., Gray R., Guimaraes Pessoa M., Hajarizadeh B., Hatzakis A., Hezode C., Himatt S.M., Hoepelman A., Hrstic I., Hui Y.-T.T., Husa P., Jahis R., Janjua N.Z., Jarcuka P., Jaroszewicz J., Kaymakoglu S., Kershenobich D., Kondili L.A., Konysbekova A., Krajden M., Kristian P., Laleman W., Lao W.-C.C., Layden J., Lazarus J.V., Lee M.-H., Liakina V., Lim Y.-S.S., Loo C.-K.K., Lukic B., Malekzadeh R., Malu A.O., Mamatkulov A., Manns M., Marinho R.T., Maticic M., Mauss S., Memon M.S., Mendes Correa M.C., Mendez-Sanchez N., Merat S., Metwally A.M., Mohamed R., Mokhbat J.E., Moreno C., Mossong J., Mourad F.H., Mullhaupt B., Murphy K., Musabaev E., Nawaz A., Nde H.M., Negro F., Nersesov A., Nguyen V.T.T., Njouom R., Ntagirabiri R., Nurmatov Z., Obekpa S., Ocama P., Oguche S., Omede O., Omuemu C., Opare-Sem O., and Opio C.K.

Abstract

Background: The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate viral hepatitis by 2030. Although no virological cure exists for hepatitis B virus (HBV) infection, existing therapies to control viral replication and prophylaxis to minimise mother-to-child transmission make elimination of HBV feasible. We aimed to estimate the national, regional, and global prevalence of HBsAg in the general population and in the population aged 5 years in 2016, as well as coverage of prophylaxis, diagnosis, and treatment. Method(s): In this modelling study, we used a Delphi process that included a literature review in PubMed and Embase, followed by interviews with experts, to quantify the historical epidemiology of HBV infection. We then used a dynamic HBV transmission and progression model to estimate the country-level and regional-level prevalence of HBsAg in 2016 and the effect of prophylaxis and treatment on disease burden. Finding(s): We developed models for 120 countries, 78 of which were populated with data approved by experts. Using these models, we estimated that the global prevalence of HBsAg in 2016 was 3.9% (95% uncertainty interval [UI] 3.4-4.6), corresponding to 291 992 000 (251 513 000-341 114 000) infections. Of these infections, around 29 million (10%) were diagnosed, and only 4.8 million (5%) of 94 million individuals eligible for treatment actually received antiviral therapy. Around 1.8 (1.6-2.2) million infections were in children aged 5 years, with a prevalence of 1.4% (1.2-1.6). We estimated that 87% of infants had received the three-dose HBV vaccination in the first year of life, 46% had received timely birth-dose vaccination, and 13% had received hepatitis B immunoglobulin along with the full vaccination regimen. Less than 1% of mothers with a high viral load had received antiviral therapy to reduce mother-to-child transmission. Interpretation(s): Our estimate of HBV prevalence in 2016 differs from previous studies, potentia

Published
2018

11. patients: a multi-center study, Turkey

Author

Karacaer, Z, Cakir, B, Erdem, H, Ugurlu, K, Durmus, G, Ince, NK, Ozturk, C, Hasbun, R, Batirel, A, Yilmaz, EM, Bozkurt, I, Sunbul, M, Aynioglu, A, Atilla, A, Erbay, A, Inci, A, Kader, C, Tigen, ET, Karaahmetoglu, G, Coskuner, SA, Dik, E, Tarakci, H, Tosun, S, Korkmaz, F, Kolgelier, S, Karadag, FY, Erol, S, Turker, K, Necan, C, Sahin, AM, Ergen, P, Iskender, G, Korkmaz, P, Eroglu, EG, Durdu, Y, Ulug, M, Deniz, SS, Koc, F, Alpat, SN, Oztoprak, N, Evirgen, O, Sozen, H, Dogan, M, Kaya, S, Altindis, M, Aslan, E, Tekin, R, Sezer, BE, Ozdemir, K, Ersoz, G, Sahin, A, Celik, I, Aydin, E, Bastug, A, Harman, R, Ozkaya, HD, Parlak, E, Yavuz, I, Sacar, S, Comoglu, S, Yenilmez, E, Sirmatel, F, Balkan, II, Alpay, Y, Hatipoglu, M, Denk, A, Senol, G, Bitirgen, M, Geyik, MF, Guner, R, Kadanali, A, Karakas, A, Namiduru, M, Udurgucu, H, Boluktas, RP, Karagoz, E, and Ormeci, N

Subjects
Chronic hepatitis B infection, Quality of life, The Hepatitis B Quality, of Life Instrument, Turkey
Abstract

Background: The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors. Methods: This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant. Results: Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided. Conclusions: The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients.

Published
2016

12. Quality of life and related factors among chronic hepatitis B-infected patients: A multi-center study, Turkey

Author

Karacaer, Z., Cakir, B., Erdem, H., Ugurlu, K., Durmus, G., Ince, N.K., Ozturk, C., Hasbun, R., Batirel, A., Yilmaz, E.M., Bozkurt, I., Sunbul, M., Aynioglu, A., Atilla, A., Erbay, A., Inci, A., Kader, C., Tigen, E.T., Karaahmetoglu, G., Coskuner, S.A., Dik, E., Tarakci, H., Tosun, S., Korkmaz, F., Kolgelier, S., Karadag, F.Y., Erol, S., Turker, K., Necan, Ceyda, Sahin, A.M., Ergen, P., Iskender, G., Korkmaz, P., Eroglu, E.G., Durdu, Y., Ulug, M., Deniz, S.S., Koc, F., Alpat, S.N., Oztoprak, N., Evirgen, O., Sozen, H., Dogan, M., Kaya, S., Altindis, M., Aslan, E., Tekin, R., Sezer, B.E., Ozdemir, K., Ersoz, G., Sahin, A., Celik, I., Aydin, E., Bastug, A., Harman, R., Ozkaya, H.D., Parlak, E., Yavuz, I., Sacar, S., Comoglu, S., Yenilmez, E., Sirmatel, F., Balkan, I.I., Alpay, Y., Hatipoglu, M., Denk, A., Senol, G., Bitirgen, M., Geyik, M.F., Guner, R., Kadanali, A., Karakas, A., Namiduru, M., Udurgucu, H., Boluktas, R.P., Karagoz, E., and Ormeci, N.

Subjects
Quality of life, antivirus agent, Adult, Male, demography, Turkey, quality of life assessment, psychology, Antiviral Agents, Article, Turkey (republic), Interviews as Topic, Hepatitis B, Chronic, antiviral therapy, middle aged, cross-sectional study, Health Status Indicators, Humans, chronic hepatitis B, controlled study, human, Prospective Studies, The Hepatitis B Quality of Life Instrument, Aged, Hepatitis B Quality of Life, interview, clinical trial, major clinical study, Chronic hepatitis B infection, hepatitis B surface antigen, female, multicenter study, Cross-Sectional Studies, Short Form 36, prospective study, health status indicator
Abstract

Background: The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors. Methods: This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant. Results: Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided. Conclusions: The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients. © 2016 The Author(s).

Published
2016

13. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B

Author

Rijckborst, V, ter Borg, MJ, Cakaloglu, Y, Ferenci, P, Tabak, F, Akdogan, M, Simon, K, Raptopoulou Gigi, M, Ormeci, N, Zondervan, PE, Verhey, E, van Vuuren, AJ, Hansen, BE, Janssen, HL, MONTALTO, Giuseppe, Rijckborst, V, ter Borg, MJ, Cakaloglu, Y, Ferenci, P, Tabak, F, Akdogan, M, Simon, K, Raptopoulou-Gigi, M, Ormeci, N, Zondervan, PE, Verhey, E, van Vuuren, AJ, Hansen, BE, Janssen, HL, and Montalto, G

Subjects
Antiviral treatment, Randomized trial, Chronic hepatitis B, HBeAg negative
Published
2010

14. DNA analysis and DNA ploidy in gastric cancer and gastric precancerous lesions

Author

Yasa, MH, Bektas, A, Yukselen, V, Akbulut, H, Camci, C, Ormeci, N, and Ondokuz Mayıs Üniversitesi

Subjects
flow cytometry, gastric cancer, ploidy, DNA analysis, precancerous lesions
Abstract

WOS: 000231641500010 PubMed: 16115177 Gastric cancer (GCa) is still a common cause of cancer-related deaths worldwide, despite improved diagnostic and therapeutic implications. Hence, early diagnosis has critical importance. Flow cytometry reveals rapid and reproducible quantification of nuclear DNA content of disaggregated tissues and assessment of its significance in various malignant and precancerous lesions. A total of 121 patients with GCa, chronic atrophic gastritis (CAG), gastric polyps, intestinal metaplasia (IM) and gastric dysplasia and 36 healthy controls were enrolled in this study. Flow cytometric measurements of DNA ploidy, total S-Phase, G(2)M-phase and proliferative indexes (PIs) were analysed on fresh gastric biopsy specimens obtained by gastroscopy. DNA aneuploidy was present in 43.75% of the GCas (p < 0.05). We found a DNA aneuploidy rate of 15.38% in CAG, 15.38% in IM and 25% in epithelial dysplasia. One of nine polyps had aneuploidy. None of the normal gastric mucosa samples showed aneuploidy. The controls had lower rates of total S-phase and PIs (p < 0.05). In conclusion, DNA flow cytometry may be offered as an objective diagnostic tool for earls detection of malignant transformation in gastric lesions.

Published
2005
Full Text
View/download PDF

15. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

Author

Razavi, H., Waked, I., Sarrazin, C., Myers, R. P., Idilman, R., Calinas, F., Vogel, W., Mendes Correa, M. C., Hezode, C., Lazaro, P., Akarca, U., Aleman, S., Balik, I., Berg, T., Bihl, F., Bilodeau, M., Blasco, A. J., Brandao Mello, C. E., Bruggmann, P., Buti, M., Calleja, J. L., Cheinquer, H., Christensen, P. B., Clausen, M., Coelho, H. S. M., Cramp, M. E., Dore, G. J., Doss, W., Duberg, Ann-Sofi, El-Sayed, M. H., Ergor, G., Esmat, G., Falconer, K., Felix, J., Ferraz, M. L. G., Ferreira, P. R., Frankova, S., Garcia-Samaniego, J., Gerstoft, J., Giria, J. A., Goncales, F. L., Jr., Gower, E., Gschwantler, M., Guimaraes Pessoa, M., Hindman, S. J., Hofer, H., Husa, P., Kåberg, M., Kaita, K. D. E., Kautz, A., Kaymakoglu, S., Krajden, M., Krarup, H., Laleman, W., Lavanchy, D., Marinho, R. T., Marotta, P., Mauss, S., Moreno, C., Murphy, K., Negro, F., Nemecek, V., Ormeci, N., Ovrehus, A. L. H., Parkes, J., Pasini, K., Peltekian, K. M., Ramji, A., Reis, N., Roberts, S. K., Rosenberg, W. M., Roudot-Thoraval, F., Ryder, S. D., Sarmento-Castro, R., Semela, D., Sherman, M., Shiha, G. E., Sievert, W., Sperl, J., Starkel, P., Stauber, R. E., Thompson, A. J., Urbanek, P., Van Damme, P., van Thiel, I., Van Vlierberghe, H., Vandijck, D., Wedemeyer, H., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Cornberg, M., Muellhaupt, B., Estes, C., Razavi, H., Waked, I., Sarrazin, C., Myers, R. P., Idilman, R., Calinas, F., Vogel, W., Mendes Correa, M. C., Hezode, C., Lazaro, P., Akarca, U., Aleman, S., Balik, I., Berg, T., Bihl, F., Bilodeau, M., Blasco, A. J., Brandao Mello, C. E., Bruggmann, P., Buti, M., Calleja, J. L., Cheinquer, H., Christensen, P. B., Clausen, M., Coelho, H. S. M., Cramp, M. E., Dore, G. J., Doss, W., Duberg, Ann-Sofi, El-Sayed, M. H., Ergor, G., Esmat, G., Falconer, K., Felix, J., Ferraz, M. L. G., Ferreira, P. R., Frankova, S., Garcia-Samaniego, J., Gerstoft, J., Giria, J. A., Goncales, F. L., Jr., Gower, E., Gschwantler, M., Guimaraes Pessoa, M., Hindman, S. J., Hofer, H., Husa, P., Kåberg, M., Kaita, K. D. E., Kautz, A., Kaymakoglu, S., Krajden, M., Krarup, H., Laleman, W., Lavanchy, D., Marinho, R. T., Marotta, P., Mauss, S., Moreno, C., Murphy, K., Negro, F., Nemecek, V., Ormeci, N., Ovrehus, A. L. H., Parkes, J., Pasini, K., Peltekian, K. M., Ramji, A., Reis, N., Roberts, S. K., Rosenberg, W. M., Roudot-Thoraval, F., Ryder, S. D., Sarmento-Castro, R., Semela, D., Sherman, M., Shiha, G. E., Sievert, W., Sperl, J., Starkel, P., Stauber, R. E., Thompson, A. J., Urbanek, P., Van Damme, P., van Thiel, I., Van Vlierberghe, H., Vandijck, D., Wedemeyer, H., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Cornberg, M., Muellhaupt, B., and Estes, C.

Abstract

The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing., Funding Agency:Gilead Sciences

Published
2014
Full Text
View/download PDF

16. Historical epidemiology of hepatitis C virus (HCV) in selected countries

Author

Bruggmann, P., Berg, T., Ovrehus, A. L. H., Moreno, C., Brandao Mello, C. E., Roudot-Thoraval, F., Marinho, R. T., Sherman, M., Ryder, S. D., Sperl, J., Akarca, U., Balik, I., Bihl, F., Bilodeau, M., Blasco, A. J., Buti, M., Calinas, F., Calleja, J. L., Cheinquer, H., Christensen, P. B., Clausen, M., Coelho, H. S. M., Cornberg, M., Cramp, M. E., Dore, G. J., Doss, W., Duberg, Ann-Sofi, El-Sayed, M. H., Ergor, G., Esmat, G., Estes, C., Falconer, K., Felix, J., Ferraz, M. L. G., Ferreira, P. R., Frankova, S., Garcia-Samaniego, J., Gerstoft, J., Giria, J. A., Goncales, F. L., Jr., Gower, E., Gschwantler, M., Guimaraes Pessoa, M., Hezode, C., Hofer, H., Husa, P., Idilman, R., Kåberg, M., Kaita, K. D. E., Kautz, A., Kaymakoglu, S., Krajden, M., Krarup, H., Laleman, W., Lavanchy, D., Lazaro, P., Marotta, P., Mauss, S., Mendes Correa, M. C., Muellhaupt, B., Myers, R. P., Negro, F., Nemecek, V., Ormeci, N., Parkes, J., Peltekian, K. M., Ramji, A., Razavi, H., Reis, N., Roberts, S. K., Rosenberg, W. M., Sarmento-Castro, R., Sarrazin, C., Semela, D., Shiha, G. E., Sievert, W., Starkel, P., Stauber, R. E., Thompson, A. J., Urbanek, P., van Thiel, I., Van Vlierberghe, H., Vandijck, D., Vogel, W., Waked, I., Wedemeyer, H., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Van Damme, P., Aleman, S., Hindman, S. J., Bruggmann, P., Berg, T., Ovrehus, A. L. H., Moreno, C., Brandao Mello, C. E., Roudot-Thoraval, F., Marinho, R. T., Sherman, M., Ryder, S. D., Sperl, J., Akarca, U., Balik, I., Bihl, F., Bilodeau, M., Blasco, A. J., Buti, M., Calinas, F., Calleja, J. L., Cheinquer, H., Christensen, P. B., Clausen, M., Coelho, H. S. M., Cornberg, M., Cramp, M. E., Dore, G. J., Doss, W., Duberg, Ann-Sofi, El-Sayed, M. H., Ergor, G., Esmat, G., Estes, C., Falconer, K., Felix, J., Ferraz, M. L. G., Ferreira, P. R., Frankova, S., Garcia-Samaniego, J., Gerstoft, J., Giria, J. A., Goncales, F. L., Jr., Gower, E., Gschwantler, M., Guimaraes Pessoa, M., Hezode, C., Hofer, H., Husa, P., Idilman, R., Kåberg, M., Kaita, K. D. E., Kautz, A., Kaymakoglu, S., Krajden, M., Krarup, H., Laleman, W., Lavanchy, D., Lazaro, P., Marotta, P., Mauss, S., Mendes Correa, M. C., Muellhaupt, B., Myers, R. P., Negro, F., Nemecek, V., Ormeci, N., Parkes, J., Peltekian, K. M., Ramji, A., Razavi, H., Reis, N., Roberts, S. K., Rosenberg, W. M., Sarmento-Castro, R., Sarrazin, C., Semela, D., Shiha, G. E., Sievert, W., Starkel, P., Stauber, R. E., Thompson, A. J., Urbanek, P., van Thiel, I., Van Vlierberghe, H., Vandijck, D., Vogel, W., Waked, I., Wedemeyer, H., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Van Damme, P., Aleman, S., and Hindman, S. J.

Abstract

Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New treatment options are becoming available, and there is a need to characterize the epidemiology and disease burden of HCV. Data for prevalence, viremia, genotype, diagnosis and treatment were obtained through literature searches and expert consensus for 16 countries. For some countries, data from centralized registries were used to estimate diagnosis and treatment rates. Data for the number of liver transplants and the proportion attributable to HCV were obtained from centralized databases. Viremic prevalence estimates varied widely between countries, ranging from 0.3% in Austria, England and Germany to 8.5% in Egypt. The largest viremic populations were in Egypt, with 6358000 cases in 2008 and Brazil with 2106000 cases in 2007. The age distribution of cases differed between countries. In most countries, prevalence rates were higher among males, reflecting higher rates of injection drug use. Diagnosis, treatment and transplant levels also differed considerably between countries. Reliable estimates characterizing HCV-infected populations are critical for addressing HCV-related morbidity and mortality. There is a need to quantify the burden of chronic HCV infection at the national level., Funding Agency:Gilead Sciences

Published
2014
Full Text
View/download PDF

17. Strategies to manage hepatitis C virus (HCV) disease burden

Author

Wedemeyer, H., Duberg, Ann-Sofi, Buti, M., Rosenberg, W. M., Frankova, S., Esmat, G., Ormeci, N., Van Vlierberghe, H., Gschwantler, M., Akarca, U., Aleman, S., Balik, I., Berg, T., Bihl, F., Bilodeau, M., Blasco, A. J., Brandao Mello, C. E., Bruggmann, P., Calinas, F., Calleja, J. L., Cheinquer, H., Christensen, P. B., Clausen, M., Coelho, H. S. M., Cornberg, M., Cramp, M. E., Dore, G. J., Doss, W., El-Sayed, M. H., Ergor, G., Estes, C., Falconer, K., Felix, J., Ferraz, M. L. G., Ferreira, P. R., Garcia-Samaniego, J., Gerstoft, J., Giria, J. A., Goncales, F. L., Jr., Guimaraes Pessoa, M., Hezode, C., Hindman, S. J., Hofer, H., Husa, P., Idilman, R., Kåberg, M., Kaita, K. D. E., Kautz, A., Kaymakoglu, S., Krajden, M., Krarup, H., Laleman, W., Lavanchy, D., Lazaro, P., Marinho, R. T., Marotta, P., Mauss, S., Mendes Correa, M. C., Moreno, C., Muellhaupt, B., Myers, R. P., Nemecek, V., Ovrehus, A. L. H., Parkes, J., Peltekian, K. M., Ramji, A., Razavi, H., Reis, N., Roberts, S. K., Roudot-Thoraval, F., Ryder, S. D., Sarmento-Castro, R., Sarrazin, C., Semela, D., Sherman, M., Shiha, G. E., Sperl, J., Starkel, P., Stauber, R. E., Thompson, A. J., Urbanek, P., Van Damme, P., van Thiel, I., Vandijck, D., Vogel, W., Waked, I., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Negro, F., Sievert, W., Gower, E., Wedemeyer, H., Duberg, Ann-Sofi, Buti, M., Rosenberg, W. M., Frankova, S., Esmat, G., Ormeci, N., Van Vlierberghe, H., Gschwantler, M., Akarca, U., Aleman, S., Balik, I., Berg, T., Bihl, F., Bilodeau, M., Blasco, A. J., Brandao Mello, C. E., Bruggmann, P., Calinas, F., Calleja, J. L., Cheinquer, H., Christensen, P. B., Clausen, M., Coelho, H. S. M., Cornberg, M., Cramp, M. E., Dore, G. J., Doss, W., El-Sayed, M. H., Ergor, G., Estes, C., Falconer, K., Felix, J., Ferraz, M. L. G., Ferreira, P. R., Garcia-Samaniego, J., Gerstoft, J., Giria, J. A., Goncales, F. L., Jr., Guimaraes Pessoa, M., Hezode, C., Hindman, S. J., Hofer, H., Husa, P., Idilman, R., Kåberg, M., Kaita, K. D. E., Kautz, A., Kaymakoglu, S., Krajden, M., Krarup, H., Laleman, W., Lavanchy, D., Lazaro, P., Marinho, R. T., Marotta, P., Mauss, S., Mendes Correa, M. C., Moreno, C., Muellhaupt, B., Myers, R. P., Nemecek, V., Ovrehus, A. L. H., Parkes, J., Peltekian, K. M., Ramji, A., Razavi, H., Reis, N., Roberts, S. K., Roudot-Thoraval, F., Ryder, S. D., Sarmento-Castro, R., Sarrazin, C., Semela, D., Sherman, M., Shiha, G. E., Sperl, J., Starkel, P., Stauber, R. E., Thompson, A. J., Urbanek, P., Van Damme, P., van Thiel, I., Vandijck, D., Vogel, W., Waked, I., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Negro, F., Sievert, W., and Gower, E.

Abstract

The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical., Funding Agency:Gilead Sciences

Published
2014
Full Text
View/download PDF

26. Evaluation of gastrointestinal involvement of Behçet's disease by nuclear medical techniques.

Author

Küçük, Özlem, Aras, Gülseren, Soylu, Ayfer, Gürler, Aysel, Tulunay, Özden, Örmeci, Necati, Düzgün, Nurşen, Bengi, Nejat, İbiş, Erkan, Akin, Asım, Küçük, O, Aras, G, Soylu, A, Gürler, A, Tulunay, O, Ormeci, N, Düzgün, N, Bengi, N, Ibiş, E, and Akin, A

Abstract

To evaluate the value of nuclear medicine procedures in the diagnosis of gastrointestinal involvement of Behcet's disease in asymptomatic patients, Tc-99m human immunoglobulin (HIG) and Tc-99m leucocyte (LC) whole body scintigraphies were performed on 30 patients with major symptoms of the disease. Comparison of the results with other diagnostic techniques showed that Tc-99m HIG whole body scanning can be a useful diagnostic aid before the disease becomes clinically active in the gastrointestinal system. [ABSTRACT FROM AUTHOR]

Published
1999
Full Text
View/download PDF

27. Treatment of biliary fistulas and cholelithiasis: is endoscopic sphincterotomy acceptable in the paediatric age group?

Author

Ih, Gökçora, Ormeci N, Abdulkadir Dökmeci, and Barlas M

Subjects
Biliary Fistula, Postoperative Complications, Adolescent, Cholelithiasis, Cysts, Common Bile Duct Diseases, Humans, Female, Gallstones, Child, Prognosis, Duodenoscopy, Sphincterotomy, Transduodenal
Abstract

Two children, both girls, aged 11 and 16 with a postoperative biliary fistula and cholelithiasis, choledochal cyst and common bile duct stones have undergone endoscopic sphincterotomy (EST), leading to a rapid recovery from their pathologies, thanks to cooperative work. In reviewing the literature we have not come across any cases of EST in our patients' age group. There were no complications during or immediately after endoscopic sphincterotomies. We believe that it has become an important and valuable rival to conventional surgical means with correct indications and in experienced hands.

28. Hepatic fascioliasis and biliary surgery

Author

Kayabali I, Ih, Gokcora, mehmet ali yerdel, and Ormeci N

Subjects
Adult, Diagnosis, Differential, Male, Fascioliasis, Liver Diseases, Parasitic, Humans, Female, Middle Aged
Abstract

This series represents seven cases of hepatic fascioliasis (HF), two diagnosed as the sequelae of the disease and five showing the parasite itself at the time of the primary surgical intervention. The mean history of the symptoms was 42.6 mths. All of the patients were initially misdiagnosed as having cholecysto- and/or coledocho-lithiasis or hepatitis. Definite diagnosis was established intraoperatively in each instant. At surgery cholecystectomy, choledochotomy with extirpation of the flukes from the biliary tree and T-tube biliary drainage was performed without any complications in five patients. The remaining two patients were suffering from recurrent cholangitic episodes and were regarded as sequelae and therefore treated with hepatic peri-arterial neurectomy with favourable results. Six patients received medical treatment involving emetine hydrochloride. Two patients failed to return for follow-up while others were seen to be well 6, 12, 24 mths and 13 and 24 yrs postoperatively, implying promising long-term results both in the active and chronic stages of HF.

31. Noncontrast-enhanced mri-based noninvasive score for portal hypertension (Chess1802): An international multicenter study

Author

Rita Golfieri, Antonio Bruno, Shenghong Ju, Sadik Bilgic, Tian-Yu Tang, Xiaoguo Li, Yang Bu, Jitao Wang, Jinqiang Liu, Yifei Huang, Ning Kang, Ruiling He, Chunqing Zhang, Necati Örmeci, Guangchuan Wang, Emrecan Çelebioğlu, Zhiwei Li, Chuan Liu, Yanna Liu, Alberta Cappelli, Zeynep Ellik, Ye Gu, Haijun Zhang, Seray Akçalar, Xiaolong Qi, Changchun Liu, Weimin An, Evren Üstüner, Özgün Ömer Asiller, Yan Wang, Dengxiang Liu, Lei Li, Cristina Mosconi, Dan Xu, Liu Y., Tang T., Ormeci N., Huang Y., Wang J., Li X., Li Z., An W., Liu D., Zhang C., Liu C., Liu J., Wang G., Mosconi C., Cappelli A., Bruno A., Akcalar S., Celebioglu E., Ustuner E., Bilgic S., Ellik Z., Asiller O.O., Li L., Zhang H., Kang N., Xu D., He R., Wang Y., Bu Y., Gu Y., Ju S., Golfieri R., Qi X., and Örmeci, Necati

Subjects
Liver Cirrhosis, medicine.medical_specialty, Cirrhosis, Liver surface nodularity, Portal venous pressure, education, Hepatic venous pressure gradient, Imaging, Liver cirrhosi, mental disorders, Medicine, Hepatic Venous Pressure Gradient, Advanced Chronic Liver Disease, Hepatology, business.industry, Advanced chronic liver disease, Liver Surface Nodularity, medicine.disease, Multicenter study, Liver cirrhosis, Portal hypertension, Original Article, Radiology, business, human activities
Abstract

Background and Aims This study aimed to determine the performance of the non-invasive score using noncontrast-enhanced MRI (CHESS-DIS score) for detecting portal hypertension in cirrhosis. Methods In this international multicenter, diagnostic study (ClinicalTrials.gov, NCT03766880), patients with cirrhosis who had hepatic venous pressure gradient (HVPG) measurement and noncontrast-enhanced MRI were prospectively recruited from four university hospitals in China (n=4) and Turkey (n=1) between December 2018 and April 2019. A cohort of patients was retrospectively recruited from a university hospital in Italy between March 2015 and November 2017. After segmentation of the liver on fat-suppressed T1-weighted MRI maps, CHESS-DIS score was calculated automatically by an in-house developed code based on the quantification of liver surface nodularity. Results A total of 149 patients were included, of which 124 were from four Chinese hospitals (training cohort) and 25 were from two international hospitals (validation cohort). A positive correlation between CHESS-DIS score and HVPG was found with the correlation coefficients of 0.36 (p, Graphical abstract

Published
2021

32. The case for simplifying and using absolute targets for viral hepatitis elimination goals

Author

Tsendsuren S. Oyunsuren, Chari Cohen, Waseem Hamoudi, Yao‐Chun Hsu, Harry L.A. Janssen, Hisham El Khayat, Manal H El-Sayed, Wan-Long Chuang, Young-Suk Lim, Mohamed Hassany, Fernando Passos Cupertino de Barros, Faisal Abaalkhail, Stefan Zeuzem, Samual S Lee, Miriam T. Levy, Imam Waked, Vassiliki Papaevangelou, James Fung, Erika Castro Batänjer, Kathryn Razavi-Shearer, Boatemaa Ntiri‐ Reid, Rosmawati Mohamed, Pagbajabyn Nymadawa, Robert Flisiak, Alnoor Ramji, Carole Seguin-Devaux, Sherif Mogawer, Béla Hunyady, Huma Qureshi, Mojca Matičič, Martin Lagging, Mark W. Sonderup, Xiaoguang Dou, Anne Oevrehus, William Sievert, Ezequiel Ridruejo, Ann-Sofi Duberg, Ahad Eshraghian, R. P. Shanmugam, Arif Nawaz, Qing Xie, Rick Dunn, Sayed Himatt, Daniel Shouval, Mendez Sanchez Nahum, Sabahattin Kaymakoglu, Vincent Wai-Sun Wong, Soek-Siam Tan, Willis Maddrey, Papu Prasad, Amjad Salamat, Stephanie Popping, Alice Lee, Maurizia Rossana Brunetto, Khalid Alswat, Peyton Thompson, Dong Joon Kim, Henry Chang, Amir Ali Sohrabpour, Ellen Dugan, Peer Brehm Christensen, David A. M. C. van de Vijver, Joaquín Cabezas, Su Wang, Ala I. Sharara, Peter Jarcuska, Karine Lacombe, Danjuma Adda, Sammy Saab, Chien-Jen Chen, Hwai I. Yang, Sanaa Said, Raymond F. Schinazi, Shyamasundaran Kottilil, Graham R. Foster, Qing Ning, Mehlika Toy, Ira M. Jacobson, Ayat R. Abdallah, Laura Cisneros, Dhondup Tashi, Naveed Z. Janjua, Moutaz Derbala, Marcelo Kugelmas, Steven L. Flamm, Angelos Hatzakis, Yusuf Yilmaz, Mark S. Sulkowski, Eugene R. Schiff, Kakharman Yesmembetov, John F. Dillon, Rittoo Prithiviputh, Carlos Eduardo Brandão-Mello, Rajender Reddy, Françoise Roudot-Thoraval, Lewis R. Roberts, Javier Crespo, Massimo Colombo, Nancy Steinfurth, I. M. Hoepelman, Kosh Agarwal, Faisal M. Sanai, Waleed Al-Hamoudi, Shuang Liu, Beat Muellhaupt, Sonjelle Shilton, Curtis Cooper, Calvin Q. Pan, Aijaz Ahmed, Wai-cheung C Lao, Alejandro Soza, Patricia Vélez‐Möller, Ibrahim Altraif, Tarik Asselah, Junko Tanaka, Badr Aljarallah, Adriana Vince, Faryal Khamis, Juan Francisco Sánchez-Ávila, Rafael Esteban Mur, Kimberly A. Brown, Saad Al-Kaabi, Ming-Lung Yu, Jonas Valantinas, Marieta Simonova, Javier García-Samaniego, Do Young Kim, Ieva Tolmane, Valentina Liakina, Antonio Craxì, Devin Razavi-Shearer, Waldemar Halota, Stuart K. Roberts, Donna Cryer, Kenneth Kabagambe, William Remak, Jeffrey V. Lazarus, Brian Conway, Sameera Ezzat, C Wendy Spearman, Karolin Falconer, Maria C Mendes Correa, Poonam Mathur, Ferruccio Bonino, Jose Luis Calleja, Said A. Al-Busafi, E. A. Croes, Tim Block, Shahin Merat, Francesco Negro, Reza Malekzadeh, Fernando L. Gonçales, Amany Zekry, Wahid Doss, Michael Ninburg, Philip Bruggmann, Man-Fung Yuen, George V. Papatheodoridis, Aasim Yusuf, David Kershenobich, Bruce R. Bacon, Abdul Rahman Bizri, Gamal Esmat, Sarah Blach, Hamad Al-Romaihi, Tatsuya Kanto, Ibrahim Mostafa, Homie Razavi, Alessio Aghemo, Mauricio Orrego, Jia-Horng Kao, Daniel Lavanchy, Zobair M. Younossi, Henry Lik-Yuen Chan, Anna Kramvis, David H. Muljono, Clemens Richter, Hla-Hla Thein, Fernando Bessone, Paulo Roberto Abrão Ferreira, Geoffrey Dusheiko, Susan Hay, Geert Robaeys, Eduardo Fassio, Loreta A. Kondili, Jorge Mera, Khalid Al-Naamani, Alaa Osman, Saleh A. Alqahtani, Joseph Doyle, Necati Örmeci, Yee Tak Hui, Heiner Wedemeyer, Laith Jamal Abu Raddad, Masayuki Kurosaki, Rui Tato Marinho, Robert G. Gish, Zaigham Abbas, Seiji Yamada, Giada Sebastiani, Cihan Yurdaydin, Maria Buti, Paulo Ferrinho, Razavi H., Blach S., Razavi-Shearer D., Abaalkhail F., Abbas Z., Abdallah A., Abrao Ferreira P., Abu Raddad L.J., Adda D., Agarwal K., Aghemo A., Ahmed A., Al-Busafi S.A., Al-hamoudi W., Al-Kaabi S., Al-Romaihi H., Aljarallah B., AlNaamani K., Alqahtani S., Alswat K., Altraif I., Asselah T., Bacon B., Bessone F., Bizri A.R., Block T., Bonino F., Brandao-Mello C.E., Brown K., Bruggmann P., Brunetto M.R., Buti M., Cabezas J., Calleja J.L., Castro Batanjer E., Chan H.L.-Y., Chang H., Chen C.-J., Christensen P.B., Chuang W.-L., Cisneros L., Cohen C., Colombo M., Conway B., Cooper C., Craxi A., Crespo J., Croes E., Cryer D., Cupertino de Barros F.P., Derbala M., Dillon J., Doss W., Dou X., Doyle J., Duberg A.-S., Dugan E., Dunn R., Dusheiko G., El Khayat H., El-Sayed M.H., Eshraghian A., Esmat G., Esteban Mur R., Ezzat S., Falconer K., Fassio E., Ferrinho P., Flamm S., Flisiak R., Foster G., Fung J., Garcia-Samaniego J., Gish R.G., Goncales F., Halota W., Hamoudi W., Hassany M., Hatzakis A., Hay S., Himatt S., Hoepelman I.M., Hsu Y.-C., Hui Y.T., Hunyady B., Jacobson I., Janjua N., Janssen H., Jarcuska P., Kabagambe K., Kanto T., Kao J.-H., Kaymakoglu S., Kershenobich D., Khamis F., Kim D.J., Kim D.Y., Kondili L.A., Kottilil S., Kramvis A., Kugelmas M., Kurosaki M., Lacombe K., Lagging M., Lao W.-C., Lavanchy D., Lazarus J.V., Lee A., Lee S.S., Levy M., Liakina V., Lim Y.-S., Liu S., Maddrey W., Malekzadeh R., Marinho R.T., Mathur P., Maticic M., Mendes Correa M.C., Mera J., Merat S., Mogawer S., Mohamed R., Muellhaupt B., Muljono D., Mostafa I., Nahum M.S., Nawaz A., Negro F., Ninburg M., Ning Q., Ntiri- Reid B., Nymadawa P., Oevrehus A., Ormeci N., Orrego M., Osman A., Oyunsuren T., Pan C., Papaevangelou V., Papatheodoridis G., Popping S., Prasad P., Prithiviputh R., Qureshi H., Ramji A., Razavi-Shearer K., Reddy R., Remak W., Richter C., Ridruejo E., Robaeys G., Roberts S., Roberts L., Roudot-Thoraval F., Saab S., Said S., Salamat A., Sanai F., Sanchez-Avila J.F., Schiff E., Schinazi R., Sebastiani G., Seguin-Devaux C., Shanmugam R.P., Sharara A., Shilton S., Shouval D., Sievert W., Simonova M., Sohrabpour A.A., Sonderup M., Soza A., Wendy Spearman C., Steinfurth N., Sulkowski M., Tan S.-S., Tanaka J., Tashi D., Thein H.-H., Thompson P., Tolmane I., Toy M., Valantinas J., Van de Vijver D., Velez-Moller P., Vince A., Waked I., Wang S., Wedemeyer H., Wong V., Xie Q., Yamada S., Yang H.-I., Yesmembetov K., Yilmaz Y., Younossi Z., Yu M.-L., Yuen M.-F., Yurdaydin C., Yusuf A., Zekry A., Zeuzem S., Medical Microbiology & Infectious Diseases, Virology, and Negro, Francesco

Subjects
ddc:616, Carcinoma, Hepatocellular, Hepatology, Hepatitis, Viral, Human, business.industry, Liver Neoplasms, ddc:616.07, medicine.disease, World Health Organization, Virology, digestive system diseases, Goal, Infectious Diseases, Absolute (philosophy), SDG 3 - Good Health and Well-being, medicine, Humans, Viral hepatitis, business, Goals, Human
Abstract

The 69th World Health Assembly endorsed the Global Health Sector Strategy for Viral Hepatitis, embracing a goal to eliminate hepatitis infection as a public health threat by 2030. This was followed by the World Health Organization's (WHO) global targets for the care and management of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These announcements and targets were important in raising awareness and calling for action; however, tracking countries’ progress towards these elimination goals has provided insights to the limitations of these targets. The existing targets compare a country's progress relative to its 2015 values, penalizing countries who started their programmes prior to 2015, countries with a young population, or countries with a low prevalence. We recommend that (1) WHO simplify the hepatitis elimination targets, (2) change to absolute targets and (3) allow countries to achieve these disease targets with their own service coverage initiatives that will have the maximum impact. The recommended targets are as follows: reduce HCV new chronic cases to ≤5 per 100000, reduce HBV prevalence among 1-year-olds to ≤0.1%, reduce HBV and HCV mortality to ≤5 per 100000, and demonstrate HBV and HCV year-to-year decrease in new HCV- and HBV-related HCC cases. The objective of our recommendations is not to lower expectations or diminish the hepatitis elimination standards, but to provide clearer targets that recognize the past and current elimination efforts by countries, help measure progress towards true elimination, and motivate other countries to follow suit.

Published
2021
Full Text
View/download PDF

33. Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real‐world chronic hepatitis C patients cohort

Author

Alkim, Huseyin, Kaymakoglu, Sabahattin, TABAK, Ömer Fehmi, GÜNŞAR, FULYA, AKHAN, SILA, İDİLMAN, RAMAZAN, DEMİR, MEHMET, ALADAĞ, MURAT, Erol, Cihan, Cavus, Bilger, Iliaz, Raim, Koklu, Hayrettin, Cakaloglu, Yilmaz, Sahin, Memduh, ERSÖZ, GALİP, Koksal, Iftihar, KARASU, ABDULLAH ZEKİ, Ozgenel, Meric, TURAN, İLKER, GÜNDÜZ, FEYZA, ATASEVEN , HÜSEYİN, Akdogan, Meral, KIYICI, MURAT, Ozkan, Hasan, Ozer, Birol, AKARSU, MESUT, Kuruuzum, Ziya, Yurdaydin, Cihan, Yozgat, Ahmet, Yilmaz, Hasan, Yilmaz, Bulent, Yildirim, Beytullah, Yildirim, Abdullah E., KÖKSAL, AYDIN ŞEREF, Yaras, Serkan, Unal, Hakan, Toka, Bilal, Simsek, Halis, Senates, Ebubekir, Poturoglu, Sule, Ozenirler, Seren, Ozbakir, Omer, Ormeci, Necati, ÖNDER, Fatih Oğuz, Kav, Taylan, Kamilli, Cemil, Inkaya, Ahmet Cagan, Gursoy, Sebnem, Gurel, Selim, Gokcan, Hale, Ensaroglu, Fatih, Cosgun, Suleyman, Celik, Ilhami, Bolat, Aylin, Baysal, Birol, Barut, Huseyin S., Balik, Ismail, Aygen, Bilgehan, Ates, Fehmi, Araz, Filiz, Akarca, Ulus S., Idilman, R, Demir, M, Aladag, M, Erol, C, Cavus, B, Iliaz, R, Koklu, H, Cakaloglu, Y, Sahin, M, Ersoz, G, Koksal, I, Karasu, Z, Ozgenel, M, Turan, I, Gunduz, F, Ataseven, H, Akdogan, M, Kiyici, M, Koksal, AS, Akhan, S, Gunsar, F, Tabak, F, Kaymakoglu, S, Akarca, US, Akarsu, M, Alkim, H, Araz, F, Ates, F, Aygen, B, Balik, I, Barut, HS, Baysal, B, Bolat, A, Celik, I, Cosgun, S, Ensaroglu, F, Gokcan, H, Gurel, S, Gursoy, S, Inkaya, AC, Kamilli, C, Kav, T, Kuruuzum, Z, Onder, FO, Ormeci, N, Ozbakir, O, Ozenirler, S, Ozer, B, Ozkan, H, Poturoglu, S, Senates, E, Simsek, H, Toka, B, Unal, H, Yaras, S, Yildirim, AE, Yildirim, B, Yilmaz, B, Yilmaz, H, Yozgat, A, Yurdaydin, C, Sakarya Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri Bölümü, Köksal, Aydın Şeref, and Toka, Bilal

Subjects
Male, Cirrhosis, Sustained Virologic Response, Sofosbuvir, viruses, medicine.medical_treatment, Hepacivirus, Liver transplantation, Gastroenterology, Cohort Studies, chemistry.chemical_compound, Liver disease, 0302 clinical medicine, 030212 general & internal medicine, Aged, 80 and over, Liver Neoplasms, Middle Aged, Infectious Diseases, Hepatocellular carcinoma, RNA, Viral, Drug Therapy, Combination, Female, 030211 gastroenterology & hepatology, Uridine Monophosphate, medicine.drug, Adult, Ledipasvir, medicine.medical_specialty, Carcinoma, Hepatocellular, Genotype, Antiviral Agents, 03 medical and health sciences, Virology, Internal medicine, Ribavirin, medicine, Humans, Aged, Fluorenes, Hepatology, business.industry, Hepatitis C, Chronic, medicine.disease, digestive system diseases, Liver Transplantation, chemistry, Benzimidazoles, Liver function, Neoplasm Recurrence, Local, business
Abstract

The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease and to analyse whether the use of LDV/SOF treatment is associated with a new occurrence of hepatocellular carcinoma (HCC) during and after LDV/SOF treatment. The Turkish Early Access Program provided LDV/SOF treatment to a total of 200 eligible CHC patients with advanced liver disease. The median follow-up period was 22 months. All patients were Caucasian, 84% were infected with genotype 1b, and 24% had a liver transplantation before treatment. The sustained virological response (SVR12) was 86.0% with ITT analysis. SVR12 was similar among patients with Child-Pugh classes A, B and C disease and transplant recipients. From baseline to SVR12, serum ALT level and MELD score were significantly improved (P < 0.001). LDV/SOF treatment was generally well tolerated. Only one patient developed a new diagnosed HCC. Seventeen of the 35 patients, who had a history of previous HCC, developed HCC recurrence during the LDV/SOF treatment or by a median follow-up of 6 months after treatment. HCC recurrence was less commonly observed in patients who received curative treatment for HCC compared with those patients who received noncurative treatment (P = 0.007). In conclusion, LDV/SOF with or without ribavirin is an effective and tolerable treatment in CHC patients with advanced liver disease. Eradication is associated with improvements in liver function and a reduced risk of developing a new occurrence of HCC.

Published
2019
Full Text
View/download PDF

34. Consensus recommendations of three-dimensional visualization for diagnosis and management of liver diseases

Author

Jiro Fujimoto, Peng Zhang, Kwan Man, Weiqi Zhang, Valérie Vilgrain, Michael Pavlides, Cosmas Rinaldi A Lesmana, Shaoxiang Zhang, Sombat Treeprasertsuk, Yingbin Liu, Hitoshi Maruyama, Hongchi Jiang, Bixiang Zhang, Sai Wen, Xianyao Quan, Hao Wen, Anand V. Kulkarni, Yinmo Yang, Xiujun Cai, Guilherme Ferreira da Motta Rezende, Hauke Lang, Xiaolong Qi, Cristina Mosconi, Xishan Hao, Qiang Li, Long R. Jiao, Chihua Fang, Wan Yee Lau, Jia Fan, Lianxin Liu, Rita Golfieri, Joo Hyun Sohn, Necati Örmeci, Antonio Bruno, Rafael Oliveira Ximenes, Jihyun An, Qiping Lu, Fang C., An J., Bruno A., Cai X., Fan J., Fujimoto J., Golfieri R., Hao X., Jiang H., Jiao L.R., Kulkarni A.V., Lang H., Lesmana C.R.A., Li Q., Liu L., Liu Y., Lau W., Lu Q., Man K., Maruyama H., Mosconi C., Ormeci N., Pavlides M., Rezende G., Sohn J.H., Treeprasertsuk S., Vilgrain V., Wen H., Wen S., Quan X., Ximenes R., Yang Y., Zhang B., Zhang W., Zhang P., Zhang S., and Qi X.

Subjects
medicine.medical_specialty, Quality control system, Consensus, Three-dimensional visualization, Hepatocellular carcinoma, IMPACT, medicine.medical_treatment, BILE-DUCT, PREOPERATIVE SIMULATION, Mature technology, Consensu, EXTENDED LEFT HEPATECTOMY, Guidelines, HILAR CHOLANGIOCARCINOMA, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, HEPATOCELLULAR-CARCINOMA, medicine, Medical physics, COMPUTED-TOMOGRAPHY, RECONSTRUCTION, Portal hypertension, Computed tomography, Hepatolithiasis, Three-dimensional printing, Science & Technology, Hepatology, Gastroenterology & Hepatology, business.industry, TRANSPLANTATION, Living donor liver transplantation, Quality control, 1103 Clinical Sciences, Visualization, Transplantation, Hepatolithiasi, Workflow, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Liver function, Hepatectomy, business, Life Sciences & Biomedicine, SURGERY SIMULATION
Abstract

Three-dimensional (3D) visualization involves feature extraction and 3D reconstruction of CT images using a computer processing technology. It is a tool for displaying, describing, and interpreting 3D anatomy and morphological features of organs, thus providing intuitive, stereoscopic, and accurate methods for clinical decision-making. It has played an increasingly significant role in the diagnosis and management of liver diseases. Over the last decade, it has been proven safe and effective to use 3D simulation software for pre-hepatectomy assessment, virtual hepatectomy, and measurement of liver volumes in blood flow areas of the portal vein; meanwhile, the use of 3D models in combination with hydrodynamic analysis has become a novel non-invasive method for diagnosis and detection of portal hypertension. We herein describe the progress of research on 3D visualization, its workflow, current situation, challenges, opportunities, and its capacity to improve clinical decision-making, emphasizing its utility for patients with liver diseases. Current advances in modern imaging technologies have promised a further increase in diagnostic efficacy of liver diseases. For example, complex internal anatomy of the liver and detailed morphological features of liver lesions can be reflected from CT-based 3D models. A meta-analysis reported that the application of 3D visualization technology in the diagnosis and management of primary hepatocellular carcinoma has significant or extremely significant differences over the control group in terms of intraoperative blood loss, postoperative complications, recovery of postoperative liver function, operation time, hospitalization time, and tumor recurrence on short-term follow-up. However, the acquisition of high-quality CT images and the use of these images for 3D visualization processing lack a unified standard, quality control system, and homogeneity, which might hinder the evaluation of application efficacy in different clinical centers, causing enormous inconvenience to clinical practice and scientific research. Therefore, rigorous operating guidelines and quality control systems need to be established for 3D visualization of liver to develop it to become a mature technology. Herein, we provide recommendations for the research on diagnosis and management of 3D visualization in liver diseases to meet this urgent need in this research field.

Published
2020

35. Clinicopathological profile of gastrointestinal tuberculosis: a multinational ID-IRI study

Author

Tolga Yakar, Zauresh Smagulova, Antonio Cascio, Ilker Inanc Balkan, Fatma Sirmatel, Tolga Duzenli, Sophia de Saram, Alpaslan Tanoglu, Serda Gulsun, Necati Örmeci, Hakan Erdem, Secil Deniz, Recep Tekin, Salih Cesur, Özlem Aydin, Nicolas Dauby, Affan Denk, Burak Ozseker, Aysegul Erdem, Ahsen Oncul, Fahad Almajid, Soline Simeon, Seniha Senbayrak, Ayse Batirel, Jon S. Friedland, Filiz Pehlivanoglu, Maiya Konkayeva, Sholpan Kulzhanova, Fatma A. Amer, Meltem Taşbakan, Ahmed Ashraf Wegdan, Tanoglu A., Erdem H., Friedland J.S., Almajid F.M., Batirel A., Kulzhanova S., Konkayeva M., Smagulova Z., Pehlivanoglu F., de Saram S., Gulsun S., Amer F., Balkan I.I., Tekin R., Cascio A., Dauby N., Sirmatel F., Tasbakan M., Erdem A., Wegdan A.A., Aydin O., Cesur S., Deniz S., Senbayrak S., Denk A., Duzenli T., Simeon S., Oncul A., Ozseker B., Yakar T., Ormeci N., Ege Üniversitesi, MÜ, İÜC, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, BAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, and Sırmatel, Fatma

Subjects
Male, Cirrhosis, medicine.medical_treatment, retrospective study, laparoscopy, Colonoscopy, multimodal imaging, Comorbidity, Gastroenterology, protionamide, 0302 clinical medicine, Laparotomy, Ascites, amikacin, Medicine, bedaquiline, Pathologie maladies infectieuses, intestine biopsy, adult, steroid, clinical trial, General Medicine, rifabutin, Microbiologie et protistologie [entomologie,phytoparasitolog.], priority journal, diabetes mellitus, histopathology, biological product, Microbiology (medical), Microbiologie et protistologie [parasitologie hum. et anim.], medicine.medical_specialty, Tuberculosis, 030106 microbiology, malignant neoplasm, Article, 03 medical and health sciences, laparotomy, Human immunodeficiency virus infection, molecular diagnosis, Humans, Gastro-intestinal, human, Retrospective Studies, colon, disease predisposition, microbiology, Immune-suppression, Endoscopy, anus, medicine.disease, major clinical study, multicenter study, aminosalicylic acid, cyclophosphamide, 0301 basic medicine, Biopsy, Antitubercular Agents, ethambutol, rifampicin, terminal ileum, colonoscopy, ofloxacin, 030212 general & internal medicine, Laparoscopy, azathioprine, medicine.diagnostic_test, Incidence (epidemiology), gastrointestinal tuberculosis, Disease Management, chronic kidney failure, cycloserine, Infectious Diseases, female, Treatment Outcome, Molecular Diagnostic Techniques, diagnostic test, Disease Susceptibility, medicine.symptom, moxifloxacin, Symptom Assessment, stomach, isoniazid, pyrazinamide, streptomycin, liver cirrhosis, patient referral, linezolid, Internal medicine, business.industry, Mycobacterium tuberculosis, human tissue, clinical feature, Treatment, Tuberculosis, Gastrointestinal, tuberculostatic agent, business, Microbiologie et protistologie [bacteriol.virolog.mycolog.]
Abstract

Data are relatively scarce on gastro-intestinal tuberculosis (GITB). Most studies are old and from single centers, or did not include immunosuppressed patients. Thus, we aimed to determine the clinical, radiological, and laboratory profiles of GITB. We included adults with proven GITB treated between 2000 and 2018. Patients were enrolled from 21 referral centers in 8 countries (Belgium, Egypt, France, Italy, Kazakhstan, Saudi Arabia, UK, and Turkey). One hundred four patients were included. Terminal ileum (n = 46, 44.2%), small intestines except terminal ileum (n = 36, 34.6%), colon (n = 29, 27.8%), stomach (n = 6, 5.7%), and perianal (one patient) were the sites of GITB. One-third of all patients were immunosuppressed. Sixteen patients had diabetes, 8 had chronic renal failure, 5 were HIV positive, 4 had liver cirrhosis, and 3 had malignancies. Intestinal biopsy samples were cultured in 75 cases (78.1%) and TB was isolated in 65 patients (86.6%). PCR were performed to 37 (35.6%) biopsy samples and of these, 35 (94.6%) were positive. Ascites samples were cultured in 19 patients and M. tuberculosis was isolated in 11 (57.9%). Upper gastrointestinal endoscopy was performed to 40 patients (38.5%) and colonoscopy in 74 (71.1%). Surgical interventions were frequently the source of diagnostic samples (25 laparoscopy/20 laparotomy, n = 45, 43.3%). Patients were treated with standard and second-line anti-TB medications. Ultimately, 4 (3.8%) patients died and 2 (1.9%) cases relapsed. There was a high incidence of underlying immunosuppression in GITB patients. A high degree of clinical suspicion is necessary to initiate appropriate and timely diagnostic procedures; many patients are first diagnosed at surgery., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2019

36. Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report

Author

Iftihar Koksal, Fehmi Tabak, Necati Örmeci, Ahmet Muzaffer Demir, Mahmut Gumus, Aydın Şeref Köksal, Sabahattin Kaymakoglu, Bilgehan Aygen, Oguz Karabay, Aygen, B, Demir, AM, Gumus, M, Karabay, O, Kaymakoglu, S, Koksal, AS, Koksal, I, Ormeci, N, Tabak, F, Sakarya Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri Bölümü, Karabay, Oğuz, and Köksal, Aydın Şeref

Subjects
medicine.medical_specialty, Hepatitis B virus, Consensus, Turkey, Chronic Liver Disease and Cirrhosis, MEDLINE, Review, Antiviral Agents, Hepatitis, Hepatitis - B, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Clinical Research, Medicine, Humans, In patient, Hepatitis B Antibodies, Intensive care medicine, Hepatitis B Surface Antigens, Gastroenterology & Hepatology, business.industry, Liver Disease, Vaccination, Gastroenterology, Hepatitis B, Health Services, medicine.disease, Emerging Infectious Diseases, Infectious Diseases, Good Health and Well Being, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Virus Activation, business, Digestive Diseases, Immunosuppressive Agents
Abstract

This consensus report includes expert opinions and recommendations regarding the screening, and if necessary, the follow-up, prophylaxis, and treatment of hepatitis B before the treatment in patients who will undergo immunosuppressive therapy due to the risk of hepatitis B reactivation emergency. To increase awareness regarding the risk of hepatitis B reactivation in immunosuppressive patients, academicians from several university health research and training centers across Turkey came together and discussed the importance of the subject, current status, and issues in accordance with the current literature data and presented solutions.

Published
2018

37. Quality of life and related factors among chronic hepatitis B-infected patients: a multi-center study, Turkey

Author

Ayse Inci, Fatma Yılmaz Karadağ, Pınar Ergen, Saygin Nayman Alpat, Rezan Harman, Ilhami Celik, Filiz Koc, Hakan Erdem, Mehmet Bitirgen, Ilknur Yavuz, Nefise Oztoprak, Ayse Batirel, Banu Cakir, Mustafa Namiduru, Esmeray Mutlu Yilmaz, Kevser Ozdemir, Emsal Aydin, Yasemin Durdu, Kenan Ugurlu, Nevin Ince, Aynur Atilla, Büşra Ergüt Sezer, Emel Aslan, Serpil Erol, Mustafa Hatipoglu, Hatice Udurgucu, Mustafa Sunbul, Ayşe Erbay, Ercan Yenilmez, Hacer Deniz Ozkaya, Yeşim Alpay, Esma Gulesen Eroglu, Mehmet Faruk Geyik, Emine Parlak, Hüseyin Tarakçı, Rodrigo Hasbun, Gunes Senol, Aynur Aynioglu, Ilkay Bozkurt, Necati Örmeci, Recep Tekin, Seher Ayten Coskuner, Gokhan Karaahmetoglu, Ebru Dik, Zehra Karacaer, Suna Seçil Öztürk Deniz, Gulsen Iskender, Selma Tosun, Fatime Korkmaz, Ilker Inanc Balkan, Ergenekon Karagoz, Fatma Sirmatel, Suzan Sacar, Ömer Evirgen, Mustafa Dogan, Ayten Kadanali, Senol Comoglu, Rahmet Guner, Ahmet Şahin, Affan Denk, Elif Tukenmez Tigen, Ceyda Necan, Aliye Bastug, Ahmet Sahin, Cinar Ozturk, Hamdi Sözen, Çiğdem Kader, Mustafa Altindiş, Şafak Kaya, Selçuk Kaya, Mehmet Ulug, Servet Kolgelier, Gül Durmuş, Kamuran Turker, Ahmet Karakaş, Gülden Ersöz, Pinar Korkmaz, Rukiye Pinar Bölüktaş, Fakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalı, Şahin, Ahmet Melih, Karacaer, Zehra, Cakir, Banu, Erdem, Hakan, Ugurlu, Kenan, Durmus, Gul, Ince, Nevin Koc, Ozturk, Cinar, Hasbun, Rodrigo, Batirel, Ayse, Yilmaz, Esmeray Mutlu, Bozkurt, Ilkay, Sunbul, Mustafa, Aynioglu, Aynur, Atilla, Aynur, Erbay, Ayse, Inci, Ayse, Kader, Cigdem, Tigen, Elif Tukenmez, Karaahmetoglu, Gokhan, Coskuner, Seher Ayten, Dik, Ebru, Tarakci, Huseyin, Tosun, Selma, Korkmaz, Fatime, Kolgelier, Servet, Karadag, Fatma Yilmaz, Erol, Serpil, Turker, Kamuran, Necan, Ceyda, Sahin, Ahmet Melih, Ergen, Pinar, Iskender, Gulsen, Korkmaz, Pinar, Eroglu, Esma Gulesen, Durdu, Yasemin, Ulug, Mehmet, Deniz, Suna Secil, Koc, Filiz, Alpat, Saygin Nayman, Oztoprak, Nefise, Evirgen, Omer, Sozen, Hamdi, Dogan, Mustafa, Kaya, Selcuk, Kaya, Safak, Altindis, Mustafa, Aslan, Emel, Tekin, Recep, Sezer, Busra Ergut, Ozdemir, Kevser, Ersoz, Gulden, Sahin, Ahmet, Celik, Ilhami, Aydin, Emsal, Bastug, Aliye, Harman, Rezan, Ozkaya, Hacer Deniz, Parlak, Emine, Yavuz, Ilknur, Sacar, Suzan, Comoglu, Senol, Yenilmez, Ercan, Sirmatel, Fatma, Balkan, Ilker Inanc, Alpay, Yesim, Hatipoglu, Mustafa, Denk, Affan, Senol, Gunes, Bitirgen, Mehmet, Geyik, Mehmet Faruk, Guner, Rahmet, Kadanali, Ayten, Karakas, Ahmet, Namiduru, Mustafa, Udurgucu, Hatice, Boluktas, Rukiye Pinar, Karagoz, Ergenekon, Ormeci, Necati, Karacaer, Z, Cakir, B, Erdem, H, Ugurlu, K, Durmus, G, Ince, NK, Ozturk, C, Hasbun, R, Batirel, A, Yilmaz, EM, Bozkurt, I, Sunbul, M, Aynioglu, A, Atilla, A, Erbay, A, Inci, A, Kader, C, Tigen, ET, Karaahmetoglu, G, Coskuner, SA, Dik, E, Tarakci, H, Tosun, S, Korkmaz, F, Kolgelier, S, Karadag, FY, Erol, S, Turker, K, Necan, C, Sahin, AM, Ergen, P, Iskender, G, Korkmaz, P, Eroglu, EG, Durdu, Y, Ulug, M, Deniz, SS, Koc, F, Alpat, SN, Oztoprak, N, Evirgen, O, Sozen, H, Dogan, M, Kaya, S, Altindis, M, Aslan, E, Tekin, R, Sezer, BE, Ozdemir, K, Ersoz, G, Sahin, A, Celik, I, Aydin, E, Bastug, A, Harman, R, Ozkaya, HD, Parlak, E, Yavuz, I, Sacar, S, Comoglu, S, Yenilmez, E, Sirmatel, F, Balkan, II, Alpay, Y, Hatipoglu, M, Denk, A, Senol, G, Bitirgen, M, Geyik, MF, Guner, R, Kadanali, A, Karakas, A, Namiduru, M, Udurgucu, H, Boluktas, RP, Karagoz, E, Ormeci, N, Sakarya Üniversitesi/Tıp Fakültesi/Temel Tıp Bilimleri Bölümü, Altındiş, Mustafa, Tıp Fakültesi, RTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Öztürk, Çınar, MÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Sözen, Hamdi, Zonguldak Bülent Ecevit Üniversitesi, Halk Sağlığı, BAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Sırmatel, Fatma, and OMÜ

Subjects
antivirus agent, Male, demography, MARITAL-STATUS, Turkey, Cross-sectional study, IMPACT, Disease, DETERMINANTS, Turkey (republic), 0302 clinical medicine, Quality of life, antiviral therapy, Health Status Indicators, Prospective Studies, 030212 general & internal medicine, Prospective cohort study, The Hepatitis B Quality of Life Instrument, food and beverages, clinical trial, General Medicine, Middle Aged, Hepatitis B, humanities, Chronic hepatitis B infection, Female, 030211 gastroenterology & hepatology, HEALTH, prospective study, Adult, medicine.medical_specialty, Chronic Hepatitis B Infection, quality of life assessment, psychology, Antiviral Agents, Article, Interviews as Topic, 03 medical and health sciences, Hepatitis B, Chronic, Chronic hepatitis, UTILITIES, Internal medicine, medicine, cross-sectional study, Humans, chronic hepatitis B, controlled study, human, Aged, Related factors, business.industry, Research, fungi, Public Health, Environmental and Occupational Health, Hepatitis B Quality of Life, interview, medicine.disease, major clinical study, COMORBIDITIES, hepatitis B surface antigen, multicenter study, Cross-Sectional Studies, Health Care Sciences & Services, Short Form 36, Multi center study, Physical therapy, Quality of Life, business, health status indicator
Abstract

WOS: 000386954300001, PubMed: 27809934, Background: The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors. Methods: This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant. Results: Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided. Conclusions: The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients.

Published
2016

38. Liver involvement in patients with brucellosis: results of the Marmara study

Author

D. Ozturk-Engin, H. Erdem, S. Gencer, S. Kaya, A. I. Baran, A. Batirel, R. Tekin, M. K. Celen, A. Denk, S. Guler, M. Ulug, H. Turan, A. U. Pekok, G. Mermut, M. Tasbakan, N. Tulek, Y. Cag, A. Inan, A. Yalci, C. Ataman-Hatipoglu, I. Gonen, A. Dogan-Celik, F. Bozkurt, S. Gulsun, M. Sunnetcioglu, T. Guven, F. Duygu, E. Parlak, H. Sozen, S. Tosun, T. Demirdal, E. Guclu, O. Karabay, N. Uzun, O. Gunal, H. Diktas, A. Haykir-Solay, A. Erbay, C. Kader, O. Aydin, A. Erdem, N. Elaldi, A. Kadanali, Z. Yulugkural, L. Gorenek, M. Altındis, S. Bolukcu, C. Agalar, N. Ormeci, Ozturk-Engin, D, Erdem, H, Gencer, S, Kaya, S, Baran, AI, Batirel, A, Tekin, R, Celen, MK, Denk, A, Guler, S, Ulug, M, Turan, H, Pekok, AU, Mermut, G, Tasbakan, M, Tulek, N, Cag, Y, Inan, A, Yalci, A, Ataman-Hatipoglu, C, Gonen, I, Sakarya Üniversitesi/İlahiyat Fakültesi/Temel İslam Bilimleri Bölümü, Kaya, Süleyman, [Ozturk-Engin, D. -- Inan, A. -- Bolukcu, S.] Haydarpasa Numune Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey -- [Erdem, H. -- Gorenek, L.] GATA Haydarpasa Training Hosp, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey -- [Gencer, S. -- Batirel, A. -- Cag, Y.] Lutfi Kirdar Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey -- [Kaya, S. -- Gulsun, S.] Diyarbakir Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Diyarbakir, Turkey -- [Baran, A. I. -- Sunnetcioglu, M.] Yuzuncu Yil Univ, Sch Med, Dept Infect Dis & Clin Microbiol, Van, Turkey -- [Tekin, R. -- Celen, M. K. -- Bozkurt, F.] Dicle Univ, Sch Med, Dept Infect Dis & Clin Microbiol, Diyarbakir, Turkey -- [Denk, A.] Firat Univ, Sch Med, Dept Infect Dis & Clin Microbiol, TR-23169 Elazig, Turkey -- [Guler, S.] Yenisehir State Hosp, Dept Infect Dis & Clin Microbiol, Kahramanmaras, Turkey -- [Ulug, M.] Private Umit Hosp, Dept Infect Dis & Clin Microbiol, Eskisehir, Turkey -- [Turan, H.] Baskent Univ, Sch Med, Dept Infect Dis & Clin Microbiol, Konya, Turkey -- [Pekok, A. U.] Private Erzurum Sifa Hosp, Dept Infect Dis & Clin Microbiol, Erzurum, Turkey -- [Mermut, G. -- Tosun, S.] Izmir Bozyaka Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Izmir, Turkey -- [Kaya, S.] Karadeniz Tech Univ, Sch Med, Dept Infect Dis & Clin Microbiol, Trabzon, Turkey -- [Tasbakan, M.] Ege Univ, Sch Med, Dept Infect Dis & Clin Microbiol, Izmir, Turkey -- [Tulek, N. -- Ataman-Hatipoglu, C.] Ankara Numune Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Ankara, Turkey -- [Yalci, A.] Ankara Univ, Sch Med, Dept Infect Dis & Clin Microbiol, TR-06100 Ankara, Turkey -- [Gonen, I.] Suleyman Demirel Univ, Sch Med, Dept Infect Dis & Clin Microbiol, TR-32200 Isparta, Turkey -- [Dogan-Celik, A. -- Yulugkural, Z.] Trakya Univ, Sch Med, Dept Infect Dis & Clin Microbiol, Edirne, Turkey -- [Guven, T.] Yildirim Beyazit Univ, Ankara Ataturk Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Ankara, Turkey -- [Duygu, F. -- Gunal, O.] Gaziosmanpasa Univ, Sch Med, Dept Infect Dis & Clin Microbiol, Tokat, Turkey -- [Parlak, E.] Ataturk Univ, Dept Infect Dis & Clin Microbiol, Sch Med, Erzurum, Turkey -- [Sozen, H.] Sitki Kocman Univ, Sch Med, Dept Anesthesiol & Reanimat, Mugla, Turkey -- [Demirdal, T.] Katip Celebi Univ, Sch Med, Dept Infect Dis & Clin Microbiol, Izmir, Turkey -- [Guclu, E. -- Karabay, O.] Sakarya Univ, Dept Infect Dis & Clin Microbiol, Sch Med, Sakarya, Turkey -- [Uzun, N.] Sisli Etfal Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey -- [Diktas, H.] Tatvan Mil Hosp, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey -- [Haykir-Solay, A.] Igdir State Hosp, Dept Infect Dis & Clin Microbiol, Igdir, Turkey -- [Erbay, A. -- Kader, C.] Bozok Univ, Sch Med, Dept Infect Dis & Clin Microbiol, Yozgat, Turkey -- [Aydin, O.] Medeniyet Univ, Dept Infect Dis & Clin Microbiol, Goztepe Training & Res Hosp, Istanbul, Turkey -- [Erdem, A.] Medeniyet Univ, Dept Pathol, Goztepe Training & Res Hosp, Istanbul, Turkey -- [Elaldi, N.] Cumhuriyet Univ, Sch Med, Dept Infect Dis & Clin Microbiol, Sivas, Turkey -- [Kadanali, A.] Umraniye Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey -- [Altindis, M.] Sakarya Univ, Sch Med, Dept Clin Microbiol, Sakarya, Turkey -- [Agalar, C.] Fatih Sultan Mehmet Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey -- [Ormeci, N.] Ankara Univ, Sch Med, Dept Gastroenterol, TR-06100 Ankara, Turkey, Gencer, Serap -- 0000-0002-3217-6305, Altindis, Mustafa -- 0000-0003-0411-9669, GENCER, SERAP -- 0000-0002-3217-6305, Elaldi, Nazif -- 0000-0002-9515-770X, and Karabay, Oguz -- 0000-0003-0502-432X

Subjects
Microbiology (medical), Adult, Male, medicine.medical_specialty, Anemia, Gastroenterology, Brucellosis, Hepatitis, Young Adult, Internal medicine, medicine, Animals, Humans, Leukocytosis, Transaminases, Retrospective Studies, Doxycycline, Leukopenia, business.industry, Bilirubin, General Medicine, Middle Aged, medicine.disease, Pancytopenia, Surgery, Anti-Bacterial Agents, Infectious Diseases, Treatment Outcome, Female, medicine.symptom, business, Rifampicin, medicine.drug
Abstract

WOS: 000336986700024, PubMed ID: 24557334, Brucellosis is a zoonotic disease that primarily affects the reticuloendothelial system. But, the extent of liver damage in due course of the disease is unclear. This study included 325 brucellosis patients with significant hepatobiliary involvement identified with microbiological analyses from 30 centers between 2000 and 2013. The patients with a parts per thousand yen5 times of the upper limit of normal for aminotransferases, total bilirubin level a parts per thousand yen2 mg/dl or local liver lesions were enrolled. Clinical hepatitis was detected in 284 patients (87.3 %) and cholestasis was detected in 215 (66.1 %) patients. Fatigue (91 %), fever (86 %), sweating (83 %), arthralgia (79 %), and lack of appetite (79 %) were the major symptoms. Laboratory tests showed anemia in 169 (52 %), thrombocytopenia in 117 (36 %), leukopenia in 81 (25 %), pancytopenia in 42 (13 %), and leukocytosis in 20 (6 %) patients. The most commonly used antibiotic combinations were doxycycline plus an aminoglycoside (n = 73), doxycycline plus rifampicin (n = 71), doxycycline plus rifampicin and an aminoglycoside (n = 27). The duration of ALT normalization differed significantly in three treatment groups (p < 0.001). The use of doxycycline and an aminoglycoside in clinical hepatitis showed better results compared to doxycycline and rifampicin or rifampicin, aminoglycoside, doxycycline regimens (p < 0.05). However, the length of hospital stay did not differ significantly between these three combinations (p > 0.05). During the follow-up, treatment failure occurred in four patients (1 %) and relapse was seen in three patients (0.9 %). Mortality was not observed. Hepatobiliary involvement in brucellosis has a benign course with suitable antibiotics and the use of doxycycline and an aminoglycoside regimen seems a better strategy in select patients.

Published
2014

39. Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia.

Author

Choudhury A, Kulkarni AV, Arora V, Soin AS, Dokmeci AK, Chowdhury A, Koshy A, Duseja A, Kumar A, Mishra AK, Patwa AK, Sood A, Roy A, Shukla A, Chan A, Krag A, Mukund A, Mandot A, Goel A, Butt AS, Sahney A, Shrestha A, Cárdenas A, Di Giorgio A, Arora A, Anand AC, Dhawan A, Jindal A, Saraya A, Srivastava A, Kumar A, Kaewdech A, Pande A, Rastogi A, Valsan A, Goel A, Kumar A, Singal AK, Tanaka A, Coilly A, Singh A, Meena BL, Jagadisan B, Sharma BC, Lal BB, Eapen CE, Yaghi C, Kedarisetty CK, Kim CW, Panackel C, Yu C, Kalal CR, Bihari C, Huang CH, Vasishtha C, Jansen C, Strassburg C, Lin CY, Karvellas CJ, Lesmana CRA, Philips CA, Shawcross D, Kapoor D, Agrawal D, Payawal DA, Praharaj DL, Jothimani D, Song DS, Kim DJ, Kim DS, Zhongping D, Karim F, Durand F, Shiha GE, D'Amico G, Lau GK, Pati GK, Narro GEC, Lee GH, Adali G, Dhakal GP, Szabo G, Lin HC, Li H, Nair HK, Devarbhavi H, Tevethia H, Ghazinian H, Ilango H, Yu HL, Hasan I, Fernandez J, George J, Behari J, Fung J, Bajaj J, Benjamin J, Lai JC, Jia J, Hu JH, Chen JJ, Hou JL, Yang JM, Chang J, Trebicka J, Kalf JC, Sollano JD, Varghese J, Arab JP, Li J, Reddy KR, Raja K, Panda K, Kajal K, Kumar K, Madan K, Kalista KF, Thanapirom K, Win KM, Suk KT, Devadas K, Lesmana LA, Kamani L, Premkumar M, Niriella MA, Al Mahtab M, Yuen MF, Sayed MH, Alla M, Wadhawan M, Sharma MK, Sahu M, Prasad M, Muthiah MD, Schulz M, Bajpai M, Reddy MS, Praktiknjo M, Yu ML, Prasad M, Sharma M, Elbasiony M, Eslam M, Azam MG, Rela M, Desai MS, Vij M, Mahmud N, Choudhary NS, Marannan NK, Ormeci N, Saraf N, Verma N, Nakayama N, Kawada N, Oidov Baatarkhuu, Goyal O, Yokosuka O, Rao PN, Angeli P, Parikh P, Kamath PS, Thuluvath PJ, Lingohr P, Ranjan P, Bhangui P, Rathi P, Sakhuja P, Puri P, Ning Q, Dhiman RK, Kumar R, Vijayaraghavan R, Khanna R, Maiwall R, Mohanka R, Moreau R, Gani RA, Loomba R, Mehtani R, Rajaram RB, Hamid SS, Palnitkar S, Lal S, Biswas S, Chirapongsathorn S, Agarwal S, Sachdeva S, Saigal S, Kumar SE, Violeta S, Singh SP, Mochida S, Mukewar S, Alam S, Lim SG, Alam S, Shalimar, Venishetty S, Sundaram SS, Shetty S, Bhatia S, Singh SA, Kottilil S, Strasser S, Shasthry SM, Maung ST, Tan SS, Treeprasertsuk S, Asthana S, Manekeller S, Gupta S, Acharya SK, K C S, Maharshi S, Asrani S, Dadhich S, Taneja S, Giri S, Singh S, Chen T, Gupta T, Kanda T, Tanwandee T, Piratvishuth T, Spengler U, Prasad VGM, Midha V, Rakhmetova V, Arroyo V, Sood V, Br VK, Wong VW, Pamecha V, Singh V, Dayal VM, Saraswat VA, Kim W, Jafri W, Gu W, Jun WY, Qi X, Chawla YK, Kim YJ, Shi Y, Abbas Z, Kumar G, Shiina S, Wei L, Omata M, and Sarin SK

Subjects
Humans, Asia epidemiology, Prognosis, Acute-On-Chronic Liver Failure therapy, Acute-On-Chronic Liver Failure etiology, Consensus
Abstract

Acute-on-chronic liver failure (ACLF) is a condition associated with high mortality in the absence of liver transplantation. There have been various definitions proposed worldwide. The first consensus report of the working party of the Asian Pacific Association for the Study of the Liver (APASL) set in 2004 on ACLF was published in 2009, and the "APASL ACLF Research Consortium (AARC)" was formed in 2012. The AARC database has prospectively collected nearly 10,500 cases of ACLF from various countries in the Asia-Pacific region. This database has been instrumental in developing the AARC score and grade of ACLF, the concept of the 'Golden Therapeutic Window', the 'transplant window', and plasmapheresis as a treatment modality. Also, the data has been key to identifying pediatric ACLF. The European Association for the Study of Liver-Chronic Liver Failure (EASL CLIF) and the North American Association for the Study of the End Stage Liver Disease (NACSELD) from the West added the concepts of organ failure and infection as precipitants for the development of ACLF and CLIF-Sequential Organ Failure Assessment (SOFA) and NACSELD scores for prognostication. The Chinese Group on the Study of Severe Hepatitis B (COSSH) added COSSH-ACLF criteria to manage hepatitis b virus-ACLF with and without cirrhosis. The literature supports these definitions to be equally effective in their respective cohorts in identifying patients with high mortality. To overcome the differences and to develop a global consensus, APASL took the initiative and invited the global stakeholders, including opinion leaders from Asia, EASL and AASLD, and other researchers in the field of ACLF to identify the key issues and develop an evidence-based consensus document. The consensus document was presented in a hybrid format at the APASL annual meeting in Kyoto in March 2024. The 'Kyoto APASL Consensus' presented below carries the final recommendations along with the relevant background information and areas requiring future studies., (© 2025. The Author(s).)

Published
2025
Full Text
View/download PDF

40. Non-cirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and management.

Author

Shukla A, Rockey DC, Kamath PS, Kleiner DE, Singh A, Vaidya A, Koshy A, Goel A, Dökmeci AK, Meena B, Philips CA, Sharma CB, Payawal DA, Kim DJ, Lo GH, Han G, Qureshi H, Wanless IR, Jia J, Sollano JD, Al Mahtab M, Muthiah MD, Sonderup MW, Nahum MS, Merican MIB, Ormeci N, Kawada N, Reddy R, Dhiman RK, Gani R, Hameed SS, Harindranath S, Jafri W, Qi X, Chawla YK, Furuichi Y, Zheng MH, and Sarin SK

Subjects
Humans, Idiopathic Noncirrhotic Portal Hypertension, Liver Cirrhosis complications, Liver Cirrhosis diagnosis, Practice Guidelines as Topic, Hypertension, Portal diagnosis, Hypertension, Portal etiology, Hypertension, Portal therapy
Abstract

Since the Asian Pacific Association for the Study of the Liver (APASL) published guidelines on non-cirrhotic portal fibrosis/idiopathic portal hypertension in 2007, there has been a surge in new information, especially with the introduction of the term porto-sinusoidal vascular disorder (PSVD). Non-cirrhotic intra-hepatic causes of portal hypertension include disorders with a clearly identifiable etiology, such as schistosomiasis, as well as disorders with an unclear etiology such as non-cirrhotic portal fibrosis (NCPF), also termed idiopathic portal hypertension (IPH). This entity is being increasingly recognized as being associated with systemic disease and drug therapy, especially cancer therapy. An international working group with extensive expertise in portal hypertension was assigned with formulating consensus guidelines to clarify the definition, diagnosis, histological features, natural history, and management of NCPF/IPH, especially in the context of PSVD. The guidelines were prepared based on evidence from existing published literature. Whenever there was paucity of evidence, expert opinion was included after detailed deliberation. The goal of this manuscript, therefore, is to enhance the current understanding and help create global consensus on the issues surrounding NCPF/IPH., Competing Interests: Declarations. Conflict of interest: There is no conflict of interest to disclose by any of the authors., (© 2024. Asian Pacific Association for the Study of the Liver.)

Published
2024
Full Text
View/download PDF

41. Clinicopathological profile of gastrointestinal tuberculosis: a multinational ID-IRI study.

Author

Tanoglu A, Erdem H, Friedland JS, Almajid FM, Batirel A, Kulzhanova S, Konkayeva M, Smagulova Z, Pehlivanoglu F, de Saram S, Gulsun S, Amer F, Balkan II, Tekin R, Cascio A, Dauby N, Sirmatel F, Tasbakan M, Erdem A, Wegdan AA, Aydin O, Cesur S, Deniz S, Senbayrak S, Denk A, Duzenli T, Siméon S, Oncul A, Ozseker B, Yakar T, and Ormeci N

Subjects
Antitubercular Agents pharmacology, Antitubercular Agents therapeutic use, Biopsy, Comorbidity, Disease Management, Disease Susceptibility, Female, Humans, Male, Molecular Diagnostic Techniques, Multimodal Imaging, Retrospective Studies, Symptom Assessment, Treatment Outcome, Tuberculosis, Gastrointestinal therapy, Mycobacterium tuberculosis, Tuberculosis, Gastrointestinal diagnosis, Tuberculosis, Gastrointestinal microbiology
Abstract

Data are relatively scarce on gastro-intestinal tuberculosis (GITB). Most studies are old and from single centers, or did not include immunosuppressed patients. Thus, we aimed to determine the clinical, radiological, and laboratory profiles of GITB. We included adults with proven GITB treated between 2000 and 2018. Patients were enrolled from 21 referral centers in 8 countries (Belgium, Egypt, France, Italy, Kazakhstan, Saudi Arabia, UK, and Turkey). One hundred four patients were included. Terminal ileum (n = 46, 44.2%), small intestines except terminal ileum (n = 36, 34.6%), colon (n = 29, 27.8%), stomach (n = 6, 5.7%), and perianal (one patient) were the sites of GITB. One-third of all patients were immunosuppressed. Sixteen patients had diabetes, 8 had chronic renal failure, 5 were HIV positive, 4 had liver cirrhosis, and 3 had malignancies. Intestinal biopsy samples were cultured in 75 cases (78.1%) and TB was isolated in 65 patients (86.6%). PCR were performed to 37 (35.6%) biopsy samples and of these, 35 (94.6%) were positive. Ascites samples were cultured in 19 patients and M. tuberculosis was isolated in 11 (57.9%). Upper gastrointestinal endoscopy was performed to 40 patients (38.5%) and colonoscopy in 74 (71.1%). Surgical interventions were frequently the source of diagnostic samples (25 laparoscopy/20 laparotomy, n = 45, 43.3%). Patients were treated with standard and second-line anti-TB medications. Ultimately, 4 (3.8%) patients died and 2 (1.9%) cases relapsed. There was a high incidence of underlying immunosuppression in GITB patients. A high degree of clinical suspicion is necessary to initiate appropriate and timely diagnostic procedures; many patients are first diagnosed at surgery.

Published
2020
Full Text
View/download PDF

42. Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study.

Author

Brouwer WP, Chan HLY, Lampertico P, Hou J, Tangkijvanich P, Reesink HW, Zhang W, Mangia A, Tanwandee T, Montalto G, Simon K, Ormeci N, Chen L, Tabak F, Gunsar F, Flisiak R, Ferenci P, Akdogan M, Akyuz F, Hirankarn N, Jansen L, Wong VW, Soffredini R, Liang X, Chen S, Groothuismink ZMA, Santoro R, Jaroszewicz J, Ozaras R, Kozbial K, Brahmania M, Xie Q, Chotiyaputta W, Xun Q, Pazgan-Simon M, Oztas E, Verhey E, Montanari NR, Sun J, Hansen BE, Boonstra A, and Janssen HLA

Subjects
Adult, Antiviral Agents therapeutic use, Female, Genotyping Techniques, Hepatitis B virus drug effects, Hepatitis B, Chronic virology, Humans, Male, Middle Aged, Multivariate Analysis, Prospective Studies, Genome-Wide Association Study methods, Hepatitis B virus pathogenicity, Hepatitis B, Chronic drug therapy, Interferon-alpha metabolism, Interferons metabolism
Abstract

Background: (Pegylated) Interferon ([Peg]IFN) therapy leads to response in a minority of chronic hepatitis B (CHB) patients. Host genetic determinants of response are therefore in demand., Methods: In this genome-wide association study (GWAS), CHB patients, treated with (Peg)IFN for at least 12 weeks ± nucleos(t)ide analogues within randomized trials or as standard of care, were recruited at 21 centers from Europe, Asia, and North America. Response at 24 weeks after (Peg)IFN treatment was defined as combined hepatitis B e antigen (HBeAg) loss with hepatitis B virus (HBV) DNA <2000 IU/mL, or an HBV DNA <2000 IU/mL for HBeAg-negative patients., Results: Of 1144 patients, 1058 (92%) patients were included in the GWAS analysis. In total, 282 (31%) patients achieved the response and 4% hepatitis B surface antigen (HBsAg) loss. GWAS analysis stratified by HBeAg status, adjusted for age, sex, and the 4 ancestry components identified PRELID2 rs371991 (B= -0.74, standard error [SE] = 0.16, P = 3.44 ×10-6) for HBeAg-positive patients. Importantly, PRELID2 was cross-validated for long-term response in HBeAg-negative patients. G3BP2 rs3821977 (B = 1.13, SE = 0.24, P = 2.46 × 10-6) was associated with response in HBeAg-negative patients. G3BP2 has a role in the interferon pathway and was further examined in peripheral blood mononuclear cells of healthy controls stimulated with IFNα and TLR8. After stimulation, less production of IP-10 and interleukin (IL)-10 proteins and more production of IL-8 were observed with the G3BP2 G-allele., Conclusions: Although no genome-wide significant hits were found, the current GWAS identified genetic variants associated with (Peg)IFN response in CHB. The current findings could pave the way for gene polymorphism-guided clinical counseling, both in the setting of (Peg)IFN and the natural history, and possibly for new immune-modulating therapies., Clinical Trials Registation: NCT01401400., (© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.)

Published
2019
Full Text
View/download PDF

43. Effect of Pretransplant Infections on Clinical Outcomes in Live-Donor Liver Transplant Recipients.

Author

Cinar G, Kalkan İA, Azap A, Kirimker OE, Balci D, Keskin O, Yuraydin C, Ormeci N, and Dokmeci A

Subjects
Adult, Contraindications, Procedure, Diabetes Mellitus epidemiology, Diabetes Mellitus etiology, Diabetes Mellitus mortality, End Stage Liver Disease mortality, End Stage Liver Disease surgery, Female, Hospitalization, Humans, Infections etiology, Liver Transplantation methods, Male, Middle Aged, Postoperative Complications etiology, Preoperative Period, Reoperation statistics & numerical data, Retrospective Studies, Risk Factors, Turkey, Young Adult, End Stage Liver Disease complications, Infections mortality, Liver Transplantation mortality, Living Donors, Postoperative Complications mortality
Abstract

Owing to impaired immune function, surgical procedures, and multiple hospitalizations, patients with end-stage liver disease are at risk for numerous infectious complications while waiting for transplantation. Infection in transplant recipients remains the main cause of mortality and morbidity, despite advances in surgical techniques and the development of new repressive agents. The purpose of this study is to examine the infections that develop during the pretransplantion period in live donor liver transplant recipients and their effect on post-transplant clinical outcomes. The retrospective analysis of adult live donor liver transplant recipients in the last 4 years was conducted at Ankara University Hospital, a 1900-bed tertiary-care university hospital, in Ankara, Turkey. Demographic characteristics, preoperative infections, and clinical outcomes were analyzed. Patients were divided into 2 groups according to whether they had developed an infection before transplantation. The diagnoses were based on clinical, laboratory, and microbiological findings. Statistical analyses were performed using Stata version 9.0 (StataCorp, College Station, Tex., United States), and P < .05 were considered statistically significant. In univariate analyses, having diabetes mellitus or a pretransplant infection, the number of pretransplant infection attacks, the need for a reoperation, and developing a post-transplant infection were the statistically significant factors associated with 1-year mortality (P < .001, χ 2 test). In multivariate analyses, diabetes mellitus (Odds ratio [OR] = 7.44, 95% confidence interval [CI], .03-45.79; P = .013), reoperation (OR = .33, 95% CI, .25-2.20; P < .001), having a pretransplantation infection (OR = 12.47, 95% CI, .011-87.67; P = .013), and the number of pretransplantation infection attacks (OR = .028, 95% CI, .013-.47; P < .001) were found to be statistically significant risk factors for 1-year mortality. Our study showed the effect of pretransplantation infections on post-transplant morbidity but not on rejection or mortality. According to the situation of patients, manageable pretransplantation infection is not an absolute contraindication for liver transplantation. Awareness of the increased risk for post-transplant infections and fast-acting antimicrobial coverage are the most important facts for patient survival., (Copyright © 2019 Elsevier Inc. All rights reserved.)

Published
2019
Full Text
View/download PDF

44. Carbapenemase-Producing Bacterial Infections in Patients With Liver Transplant.

Author

Cinar G, Kalkan İA, Azap A, Kirimker OE, Balci D, Keskin O, Yuraydin C, Ormeci N, and Dokmeci A

Subjects
Adult, Aged, Bacterial Proteins, Enterobacteriaceae Infections immunology, Female, Humans, Immunocompromised Host, Incidence, Liver Transplantation mortality, Male, Middle Aged, Postoperative Complications immunology, Retrospective Studies, Turkey, beta-Lactamases, Drug Resistance, Microbial, Enterobacteriaceae Infections epidemiology, Liver Transplantation adverse effects, Postoperative Complications microbiology
Abstract

Carbapenemase-producing Enterobacteriacea (CPE) cause serious and life-threatening infections. They are resistant to carbapenems and many other classes of commonly used antimicrobial agents; therefore, managing infections caused by them poses a substantial challenge in clinical practice. They can also cause morbidity and mortality in patients with liver transplant. A retrospective analysis of CPE culture-positive patients with a history of liver transplant can help to examine the epidemiology and microbiology of these bacteria, as well as gain information on the possible infection sources, susceptibility patterns, and expected mortality in infected populations. In addition, study of these bacteria could help formulate a consensus on the appropriate use of empirical and directed antibiotic therapy, which can effectively reduce infections in these patients. We reviewed the medical records of 142 subjects who underwent liver transplantation at Ankara University Hospital, a 1900-bed tertiary care university hospital, in Ankara, Turkey, between January 2014 and August 2018. Patients showing signs of infection with culture positivity for CPE-producing organisms were included from the study. Statistical analysis was performed and a value of P < .05 is considered statistically significant. In most cases, the source of infection was the abdomen. Klebsiella species was also predominant in these cases. Model for End-Stage Liver Disease scores and length of hospital stay were higher and statistically significant when compared to patients who were CPE negative. Mortality was highest in the CPE-positive group. Infection is the most important cause of mortality and morbidity after liver transplantation and increases the cost of treatment. Regarding the culture sensitivity patterns and resistance mode, empirical therapy with carbapenems does not produce a solid result. The high mortality observed with these infections reflects very limited therapeutic options., (Copyright © 2019 Elsevier Inc. All rights reserved.)

Published
2019
Full Text
View/download PDF

45. Inflammatory markers C-reactive protein and PLR in relation to HCC characteristics.

Author

Suner A, Carr BI, Akkiz H, Uskudar O, Kuran S, Tokat Y, Tokmak S, Ballı T, Ulku A, AkCam T, Delik A, Arslan B, Doran F, YalCın K, Ekinci N, Yilmaz S, Ozakyol A, Yücesoy M, BahCeci HI, Polat KY, Şimsek H, Ormeci N, Sonsuz A, Demir M, KılıC M, Uygun A, Demir A, Altıntas E, Karakulah G, Temel T, and Bektas A

Abstract

Introduction: Several markers of systemic inflammation, including blood C-reactive protein, platelet lymphocyte ratio (PLR) and neutrophil lymphocyte ratio (NLR) have been identified as independent prognosticators for hepatocellular carcinoma (HCC)., Methods: To attempt to understand the significance of these markers, they were examined in relation to 4 tumour parameters, namely maximum tumour diameter (MTD), tumour multifocality, portal vein thrombosis (PVT) and blood alpha-fetoprotein (AFP) levels., Results: Using linear and logistic regression models, we found that C-reactive protein and PLR on single variables, were statistically significantly related to the tumour parameters. In a logistic regression final model, CRP was significantly related to MTD, AFP and PVT, and the Glasgow Index significantly related to MTD and AFP. Results of the area under the receiver operating characteristic curves (ROC), showed that the areas for PLR and CRP were statistically significant for high versus low MTD and for presence versus absence of PVT. CRP alone was significant for high versus low AFP., Conclusions: These analyses suggest that the prognostic usefulness of the inflammatory markers PLR and CRP (but not NLR) may be due to their reflection of parameter values for tumour growth and invasiveness., Competing Interests: Conflicts of interest Authors declare no conflict of interest. All authors have read and agree with this paper.

Published
2019
Full Text
View/download PDF

46. Quality of life and related factors among chronic hepatitis B-infected patients: a multi-center study, Turkey.

Author

Karacaer Z, Cakir B, Erdem H, Ugurlu K, Durmus G, Ince NK, Ozturk C, Hasbun R, Batirel A, Yilmaz EM, Bozkurt I, Sunbul M, Aynioglu A, Atilla A, Erbay A, Inci A, Kader C, Tigen ET, Karaahmetoglu G, Coskuner SA, Dik E, Tarakci H, Tosun S, Korkmaz F, Kolgelier S, Karadag FY, Erol S, Turker K, Necan C, Sahin AM, Ergen P, Iskender G, Korkmaz P, Eroglu EG, Durdu Y, Ulug M, Deniz SS, Koc F, Alpat SN, Oztoprak N, Evirgen O, Sozen H, Dogan M, Kaya S, Kaya S, Altindis M, Aslan E, Tekin R, Sezer BE, Ozdemir K, Ersoz G, Sahin A, Celik I, Aydin E, Bastug A, Harman R, Ozkaya HD, Parlak E, Yavuz I, Sacar S, Comoglu S, Yenilmez E, Sirmatel F, Balkan II, Alpay Y, Hatipoglu M, Denk A, Senol G, Bitirgen M, Geyik MF, Guner R, Kadanali A, Karakas A, Namiduru M, Udurgucu H, Boluktas RP, Karagoz E, and Ormeci N

Subjects
Adult, Aged, Antiviral Agents therapeutic use, Cross-Sectional Studies, Female, Health Status Indicators, Humans, Interviews as Topic, Male, Middle Aged, Prospective Studies, Turkey, Hepatitis B, Chronic drug therapy, Hepatitis B, Chronic psychology, Quality of Life
Abstract

Background: The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors., Methods: This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant., Results: Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided., Conclusions: The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients.

Published
2016
Full Text
View/download PDF

47. PAIR vs Örmeci technique for the treatment of hydatid cyst.

Author

Ormeci N

Subjects
Anticestodal Agents therapeutic use, Echinococcosis diagnostic imaging, Echinococcosis drug therapy, Humans, Severity of Illness Index, Suction methods, Ultrasonography, Watchful Waiting, Echinococcosis surgery, Punctures methods
Abstract

Hydatid disease is caused by the larval stages of Echinococcus Granulosus. Most patients with hydatid disease have no symptoms, unless there is compression of vital organs such as the hepatic veins, portal vein, hepatic artery in the liver, bronchia in the lungs or the brain, resulting in life threatening complications like anaphylactic shock and sudden death. There are four treatment strategies for cystic echinococcosis (CE)- surgery, percutaneous methods, medical treatments and watch and wait strategies. Medical treatment with albendazol, mebendazole or prazyquentel may cure only 2/3 of patients with CE. More than 30% of patients will reoccur after stopping the treatment. Watch and wait strategy is followed for asymptomatic and small cysts or CE type IV and Type V cysts. Surgical treatments were the gold standard for treatment of CE until the last 30 years. Consequently, surgical methods decreased while percutaneous methods of treatment increased. Due to higher mortality, morbidity, recurrence rates, longer hospital stays and higher costs in comparison to percutaneous methods like PAIR and ÖRMECİ technique, surgical treatment must be limited for the complicated hydatid cyst. Both the PAIR and Örmeci techniques are safe and effective. However, the Örmeci technique offers a simpler, inexpensive method of treatment, with no mortality, lower morbidity, low recurrence rate, while being out patient based. It can be used as the first choice of treatment modality in patients with cysts type CE type one, CE type two, CE Type 3A and CE Type 3B. In this review, treatment modalities for CE, but mainly percutaneous treatment, will be discussed.

Published
2014
Full Text
View/download PDF

48. Amantadine in non-responder patients with chronic hepatitis C: a randomized prospective study.

Author

Palabıyıkoğlu M, Ormeci N, Ekiz F, Beyler AR, Erdem H, Dökmeci A, Ozkan H, Köklü S, and Coban S

Subjects
Aged, Alanine Transaminase blood, Amantadine adverse effects, Antiviral Agents adverse effects, Drug Resistance, Multiple, Viral, Drug Therapy, Combination, Female, Hepacivirus genetics, Hepatitis C, Chronic blood, Hepatitis C, Chronic diagnosis, Humans, Interferon alpha-2, Interferon-alpha therapeutic use, Male, Middle Aged, Polyethylene Glycols therapeutic use, Prospective Studies, RNA, Viral blood, Recombinant Proteins therapeutic use, Ribavirin therapeutic use, Treatment Outcome, Turkey, Viral Load, Amantadine therapeutic use, Antiviral Agents therapeutic use, Hepatitis C, Chronic drug therapy
Abstract

Background/aims: The management of non-responders (NR) represents the most challenging of all aspects in the care of patients with chronic hepatitis C (CHC). The purpose of the study was to evaluate the efficacy of amantadine., Methodology: Fourty- three patients with CHC who did not respond to prior combination therapy [IFNα-2a plus ribavirin for 48 weeks] were enrolled into the study. The first group (n=21) was administered pegylated IFN-α2a (180 mcg/week) plus ribavirin (1000-1200 mg/day) and amantadine (200mg/day) for 48 weeks. After discontinuation of therapy, patients were followed-up for an additional 24 weeks. The second group (n=22) received only amantadine (200mg/day) daily for at least 24 weeks (mean 96 weeks) and starting from the 24th week, HCV-RNA was assessed every 12 weeks without discontinuation of therapy., Results: Mean ALT levels before treatment were 115.30 units in the first and 107.73 units in the second group whereas they were 48.38 and 54.76 units, respectively, after the treatment (p<0.001 for both). Sustained viral response rate for the first group at the 72nd week was 52.3% (11/21) (p<0.025). Among patients receiving amantadine, 1 patient became HCV-RNA negative at the 24th and 3 patients at the 48th week (response rate at week 48 was 18.2%), 1 patient at the second year and 1 patient at the fourth year of the treatment (p=0.031)., Conclusions: Amantadine has a potential anti-inflammatory activity that can be a safe alternative for NR-CHC subjects to combination therapy.

Published
2012
Full Text
View/download PDF

49. Pegylated interferon alfa-2B for chronic delta hepatitis: 12 versus 24 months.

Author

Ormeci N, Bölükbaş F, Erden E, Coban S, Ekiz F, Erdem H, Palabıyıkoğlu M, Beyler AR, Balık I, Bölükbaş C, Nazlıgül Y, and Köklü S

Subjects
Adult, Antiviral Agents administration & dosage, Antiviral Agents therapeutic use, Female, Humans, Interferon alpha-2, Interferon-alpha administration & dosage, Liver Function Tests, Male, Middle Aged, Polyethylene Glycols administration & dosage, Recombinant Proteins administration & dosage, Recombinant Proteins therapeutic use, Treatment Outcome, Hepatitis D, Chronic drug therapy, Interferon-alpha therapeutic use, Polyethylene Glycols therapeutic use
Abstract

Background/aims: The aim of this study was to evaluate the efficacy of pegylated interferon (PEG-IFN) alfa-2b for short (one year) and long (two years) terms of treatment for chronic hepatitis D., Methodology: Eighteen patients with chronic hepatitis D were administered PEG-IFN alfa-2b 1.5μg/kg twice weekly for 1 month, after which they were randomly assigned (2:1) to receive PEG-IFN alfa-2b 1.5μg/kg/wk for an additional 23 months (n=11; group 1) or 11 months (n=7; group 2). All patients were followed-up for 6 months after completing therapy., Results: In group 1, there was no significant difference between HDV-RNA and ALT levels at follow-up compared with baseline (p=0.219 and p=0.624, respectively). However, in group 2, HDVRNA levels, but not ALT levels, were significantly lower at the end of follow-up (EOF) than at baseline (p=0.016 and p=0.237, respectively). Three patients, all in group 2, had undetectable hepatitis B surface antigen (HBsAg) at the end of followup (EOF). However, there was no patient who had undetectable HBsAg in group I (p=0.043). There were statistical differences for all 18 patients in terms of baseline levels of HDV-RNA compared to end of treatment (EOT) (p=0.021) and EOF (p=0.003)., Conclusions: Extending therapy from 12 to 24 months conferred no additional advantage in terms of HDV-RNA suppression and ALT normalisation.

Published
2011
Full Text
View/download PDF

50. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B.

Author

Rijckborst V, ter Borg MJ, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Raptopoulou-Gigi M, Ormeci N, Zondervan PE, Verhey E, van Vuuren AJ, Hansen BE, and Janssen HL

Subjects
Adolescent, Adult, Aged, Antiviral Agents administration & dosage, Chi-Square Distribution, Double-Blind Method, Drug Therapy, Combination, Female, Hepatitis B Surface Antigens blood, Hepatitis B e Antigens blood, Hepatitis B, Chronic immunology, Humans, Interferon alpha-2, Interferon-alpha administration & dosage, Liver Function Tests, Male, Middle Aged, Polyethylene Glycols administration & dosage, Recombinant Proteins, Ribavirin administration & dosage, Treatment Outcome, Antiviral Agents therapeutic use, Hepatitis B, Chronic drug therapy, Interferon-alpha therapeutic use, Polyethylene Glycols therapeutic use, Ribavirin therapeutic use
Abstract

Objectives: Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B patients are at high risk of treatment relapse after any antiviral therapy. Combining peginterferon alpha-2a with ribavirin might improve sustained response rates., Methods: Overall, 138 HBeAg-negative chronic hepatitis B patients were randomized to receive monotherapy (peginterferon alpha-2a 180 microg weekly plus placebo) or combination therapy (peginterferon alpha-2a weekly plus ribavirin 1,000 or 1,200 mg daily, depending on body weight) for 48 weeks. Post-treatment follow-up lasted 24 weeks. Analyses were based on the modified intention-to-treat population after exclusion of five patients., Results: At the end of follow-up, 14 (20%) of 69 patients assigned to monotherapy and 10 (16%) of 64 assigned to combination therapy had a combined response (hepatitis B virus (HBV) DNA <10,000 copies/ml (<1,714 IU/ml) and a normal alanine aminotransferase level, P=0.49). At the end of treatment, more patients had a combined response (25 (36%) vs. 26 (41%) in the monotherapy and combination therapy group, respectively, P=0.60), but subsequently relapsed during follow-up. Serum HBV DNA and hepatitis B surface antigen (HBsAg) levels decreased during treatment (mean change at week 48 compared with baseline -3.9 vs. -2.6 log copies/ml, P<0.001 and -0.56 vs. -0.34 log IU/ml, P=0.23, respectively). HBV DNA levels relapsed after treatment discontinuation; HBsAg remained at end-of-treatment levels. In general, combination therapy was well tolerated, although it was associated with a higher risk of anemia and neutropenia., Conclusions: Treatment with peginterferon alpha-2a resulted in a limited sustained response rate in HBeAg-negative chronic hepatitis B patients. Addition of ribavirin did not improve response to therapy.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results